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Fibrosing diseases involve the formation of inappropriate scar tissue, but what 
drives fibrosis is unclear. Idiopathic pulmonary fibrosis involves the formation of excess 
scar tissue in the lungs. Sialidases (also called neuraminidases) are enzymes that 
desialylate glycoconjugates by cleaving terminal sialic acids from the glycoconjugates. 
Our lab previously found that a sialylated serum glycoprotein called serum amyloid P 
(SAP) inhibits fibrosis, and that sialidases attenuate SAP function. Mammals have four 
different sialidases, NEU1 – 4. In this dissertation, I show that extensive desialylation of 
glycoconjugates and upregulation of the sialidase NEU3 is observed in the fibrotic 
lesions in human and mouse lungs. NEU3 is upregulated in the bronchoalveolar lavage 
(BAL) fluid of the fibrotic mouse lungs in bleomycin-induced pulmonary fibrosis mouse 
model studies. Fibrosis-associated signals such as transforming growth factor-β1 (TGF-
β1) and interleukin (IL)-6 upregulate NEU3 in a variety of human lung cells. 
Conversely, recombinant human NEU3 upregulates extracellular accumulation of active 
TGF-β1 and upregulates IL-6 in human peripheral blood mononuclear cells (PBMC). 
NEU3 also desialylates the human latency associated glyco-peptide (LAP) protein, 
which holds TGF-β1 in an inactive state, releasing active TGF-β1. Compared to wild-
type mice, mice lacking NEU3 have significantly less bleomycin-induced pulmonary 
fibrosis, reduced TGF-β1 staining in the lungs after bleomycin-assault, and reduced 
protein, cells, and IL-6 levels in the lung fluid, providing genetic evidence for the role of 




and oseltamivir (Tamiflu), work well on viral and mouse sialidases, but relatively poorly 
on human sialidases. In the bleomycin-induced pulmonary fibrosis mouse model, daily 
intraperitoneal injections of either DANA or oseltamivir at 10 mg / kg, starting at day 10 
after bleomycin insult, strongly attenuated pulmonary fibrosis at day 21. The currently 
studied NEU3 inhibitors have relatively poor efficacies; thus, we designed a new class of 
small molecule NEU3 inhibitors. Some of our designed inhibitors have nanomolar IC50 
values for the inhibition of recombinant human NEU3 releasing active TGF-β1 from the 
recombinant human latent TGF-β1, and inhibition of the NUE3-induced accumulation of 
IL-6 in human PBMC. One of our small molecule inhibitors given as daily 0.1 mg/kg 
injections, and two inhibitors as daily 1 mg/ kg injections, starting at day 10 after 
bleomycin insult, strongly attenuated pulmonary fibrosis at day 21 in the bleomycin-
induced fibrosis mouse model. All of these results suggest that a NEU3-to-fibrosis-to-
NEU3 positive feedback loop helps to potentiate pulmonary fibrosis. NEU3 could be a 
suitable target to develop treatments for lung fibrosis and our NEU3 inhibitors might be 
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AMPCA 4-amino-1-methyl-2-piperidine carboxylic acid 
BAL Bronchoalveolar lavage 
BSA Bovine serum albumin 
CRP C – reactive protein 
DAMP Damage-associated molecular patterns 
DANA 2-Deoxy-2,3-dehydro-n-acetyl-neuraminic acid 
ECM Extra cellular matrix 
EMT Epithelial-to-mesenchymal transition 
ER Endoplasmic reticulum 
FDA Food and Drug Administration 
IL Interleukin 
IgG Immunoglobulin 
IC Inhibition constant 
ILD Interstitial lung disease 
IPF Idiopathic pulmonary fibrosis 
LAP Latency associated peptide / Latency associated glycopeptide 
LTBP Latent TGF-β-binding protein 
MP Methyl picolinate 
MALII Maackia Amurensis Lectin II 




PNA Peanut Agglutinin 
PBS Phosphate buffered saline 
PMN Peripheral blood neutrophils 
SAP Serum amyloid P 
SNA Sambucus Nigra Lectin 
TGF-β1 Transforming growth factor-β1 
2AP 2-acetyl pyridine 
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Fibrosis is a disease that involves an increased amount of scar tissue appearing in 
an internal organ. In a fibrosing disease, an insult or an injury to an internal organ 
initiates a uncontrolled wound repair mechanism which leads to a progressive increase in 
the deposition of scar tissue, eventually leading to organ failure and death [1, 2]. There 
are more than 60 different fibrosing diseases and it is estimated that approximately 45% 
of deaths in the western world are attributed to diseases where fibrosis was a significant 
factor [3-5]. One tissue that can develop fibrosis is the lung [5]. The lungs are directly 
exposed to external harmful environmental factors present in air, which can cause a 
recurring injury in the lungs, initiating  a repeated wound healing response and 
eventually causing lung-fibrosis [6-9]. 
 
Interstitial lung disease (ILD) is a general term for a group of diseases that 
includes idiopathic pulmonary fibrosis (IPF). By definition, IPF is chronic inflammatory 
disorder which is characterized by the accumulation of scar tissue in the lungs [10]. With 
an incidence rate of 2 – 30 cases per 100,000 person-years, this translates to a population 
prevalence of ~3 million people worldwide [10, 11]. IPF has a survival rate of only 30% 
within five years after initial diagnosis, and has an incidence of 1 in 400 in patients older 
than 65 years [12]. Despite the high prevalence of IPF, there are only two FDA-




[13]. The limited knowledge of the underlying mechanism of IPF progression can be one 
reason for very few therapeutics option against IPF. Thus, there is a great need to 
understand the mechanisms behind IPF and its progression to create better therapeutic 
strategies. 
 
In the process of finding therapeutics against pulmonary fibrosis, our lab has 
found that a serum protein called Serum Amyloid P (SAP) is important in regulating 
fibrosis-associated cell differentiation and thus, can attenuate fibrosis in mammals [14-
16]. Further studies from our lab reported that the sialylated version of the SAP protein 
has the potential to attenuate fibrosis-associated cell differentiation [17]. When the 
monosaccharide known as sialic acid is present on SAP, it is called sialylated SAP, and 
when the sialic acid is removed from SAP, it is referred to as desialylated SAP. The 
process of removing sialic acid from SAP is performed by a group of enzymes called 
neuraminidases or sialidases.  
 
Sialidases are widely distributed in nature from viruses, bacteria, protozoa, and 
mammals [18, 19]. Viruses such as influenza require sialidase to release the virus from 
the sialic acids on the outside of a host cell [20]. The bacterial respiratory pathogen 
Pseudomonas aeruginosa uses a sialidase to colonize the lungs [21]. The sialidase NanA 
from Streptococcus pneumoniae causes downregulation of tight junction protein 
expression in endothelial cells and allows bacterial invasion through the blood-brain 




sialidases, named NEU1, NEU2, NEU3, and NEU4. NEU1 is in the lysosome [23-25], 
NEU2 is a soluble, cytosolic enzyme, and NEU4 has 2 isoforms, one throughout the 
mitochondria, and the other on intracellular membranes [26-28]. NEU3 is in endosomes 
and on the extracellular side of the plasma membrane, and under some conditions, can 
be released from the membrane to the extracellular environment [29]. Sialidases are 
known to be associated with inflammation in mammals [30-36]. A recent study reported 
that sialidase NEU1 is upregulated in IPF [37]. In a study of human patients with IPF, 8 
of 9 IPF patients had a high sialidase activity in the lung bronchoalveolar lavage (BAL) 
fluid, while the healthy controls showed no detectable sialidase activity [38]. These 
studies point towards a significant involvement of sialidases in progression of pulmonary 
fibrosis. 
 
Here in this dissertation, I explored the role of sialidases in the progression of 
IPF using in-vitro human cell types study and in-vivo mouse model studies. I report my 
contributions to a possible mechanism that shows targeting sialidases could be an 
efficient strategy in controlling the progression and reversing pulmonary fibrosis. 
Further, I report my contributions in developing sialidase inhibitors as potential 
therapeutics for treating IPF. Before describing the experimental details and the data 
acquired, I will briefly introduce some terms that I have used throughout in my projects 






1.2. Neuraminidases, also called sialidases 
In eukaryotic cells, some proteins undergo post-translational modification. One 
type of post-translational modification is adding a chain of sugar molecules onto specific 
amino acids in the protein sequence and this process is called glycosylation [39, 40]. The 
chain of sugar molecules formed on the protein is called a glycan structure and the 
modified protein is called a glycoconjugate [39, 41]. One of the steps in glycosylation is 
sialylation, in which the distal tips of glycan structures on a glycoconjugates are capped 
by the addition of a sugar called sialic acid [42-44]. In many cases, the addition of sialic 
acid on the distal tips of glycan structures makes a glycoconjugate fully functional and 
can alter a wide variety of physiological and pathological processes [41, 44-46]. Loss or 
removal of sialic acid from the tip of the glycan structure of a glycoconjugate can cause 
the glycoconjugate to completely lose its functional ability [44, 45, 47]. 
 
The removal of sialic acid from a glycoconjugate is an enzymatic process carried 
out by a group of enzymes called neuraminidases (also called sialidases). As mentioned 
above, sialidases are widely distributed in nature from viruses, bacteria, protozoa, and all 
mammals [18, 19]. Mammals have four sialidases, NEU1 – NEU4. In mammals, all 
these sialidases play an important role in catabolism of glycoconjugates, modulation of 
the sialylated content on cell membranes, skeletal muscle architecture central nervous 
system, and modulation of immune function [48-50]. Considering these important 





As mentioned above, many studies have shown that dysregulation of sialidase levels can 
cause severe pathological conditions like lymphomas, leukemias, and inflammation. 
NEU1 plays a key role in potentiating airway inflammation in asthma [53], and 
upregulated levels of NEU1 act as a novel modulator of inflammation in atherosclerosis 
[54]. NEU3 is upregulated in, and is important for the survival of, cancerous cells in 
colon [55], renal [56], ovarian [57], and prostate cancers [58].  Two studies also reported 
upregulation of some sialidases in IPF in mammals [37, 38]. 
 
1.3. Mammalian lungs and pathophysiology of IPF 
The major function of mammalian lungs is to perform gas exchange. To carry out 
gas exchange properly, different cell types are required. Alveolar epithelial cells are 
crucial in forming small air sacs (called alveoli) that facilitate gas exchange [59]. The 
connecting space between the walls of these alveoli is called the interstitium of the lungs 
[60]. The alveoli and the interstitium together are supported by pulmonary fibroblasts. 
They play an important role in the repair and remodeling process after any injury to the 
lungs [61]. Another cell type in the lung is resident immune cells called alveolar 
macrophages, which play an important role in the clearance of any harmful agents 
encountered in the lungs [62]. Other than these cells, the lungs are also occupied by 
circulatory immune cells from blood collectively called peripheral blood mononuclear 
cells (PBMC) which consists of a mixture of different lymphocytes (T cells, B cells, and 
natural killer cells), dendritic cells, and monocytes [63]. The monocytes are attracted to 




macrophages or spindle-shaped fibroblast-like cells called fibrocytes, which are detected 
in pulmonary fibrosis [14, 64, 65]. 
 
The aforementioned cell types generate a cascade of signals as a part of the repair 
mechanism during a lung injury or in response to the intrusion of a harmful agent. As the 
result of an injury or on encountering a harmful agent, the aforementioned cell types get 
damaged or apoptotic [66, 67]. These damaged or dying cells release signals in the form 
of cell-to-cell membrane-bound signals, secreted proteins or some danger molecules 
known as damage-associated molecular patterns (DAMPS) to initiate a repair 
mechanism [68]. The repair signaling molecules  are primarily secreted in the alveoli or 
in the supporting interstitium [69]. In response to these repair signals, the surrounding 
healthy or un-injured cell types initiate another signaling cascade or undergo a 
morphological change in an attempt to potentiate the repair process, which is a timely 
and regulated series of events in normal conditions [70, 71] . If this repair process is 
dysregulated, it becomes chronic and an active non-healing injury site [71].  In the case 
of an internal organ like lungs, the dysregulated chronic non-healing injury affects the 
architecture of the lungs, primarily by forming inappropriate scar tissue [5, 10]. The scar 
tissue in lungs is deposited in the interstitium space. The deposited scar tissue impedes 
gas exchange causing difficulty in breathing and eventually leads to IPF. The 




(i) Epithelial-to-mesenchymal transition (EMT), where the transition causes the alveolar 
epithelial cells to acquire mesenchymal features of invasion, migration, and production 
of extracellular matrix (ECM) [72, 73]. 
(ii) Differentiation of pulmonary fibroblasts to myofibroblasts which form fibroblastic 
foci and produce ECM components [74]. The formation of these fibroblastic foci leads 
to worsening lung compliance [11, 75]. 
(iii) Excessive deposition of extracellular matrix (ECM) components like hyaluronan, 
periostin, versican, fibulin, fibrillin, fibronectin, proteoglycans, and collagen [76-78], in 
the interstitium, which makes the lung tissue hard and stiff, eventually decreasing lung 
functionality [11, 79, 80]. 
(iv) Accumulation of abnormal levels of  fibrosis-associated cytokines, secreted by 
immune cells locally at the active site of fibrosis or by non-immune lung cell types like 
mesenchymal cells, myofibroblasts, and epithelial cells [9, 81-83].  
 
These are some of the primarily observed pathological and physiological 
characteristic features of IPF. A couple of the features, like the abnormal levels of 
fibrosis-associated cytokines, can have adverse effects on the surrounding healthy tissues 
also. Among all of the fibrosis-associated cytokines, transforming growth factor-β1 







1.4. Transforming growth factor – β1 (TGF-β1) 
TGF-β1 at physiologically regulated levels are important for many roles like cell 
proliferation and growth, apoptosis, and maintaining immune homeostasis [85-87]. TGF-
β1 is a pleotropic cytokine and its dysregulation plays a key role in the progression of 
pulmonary fibrosis [88]. 
 
TGF-β1 is synthesized as a precursor polypeptide consisting of latency-
associated peptide (LAP) and the active TGF-β1 product [89]. The precursor polypeptide 
is processed in the endoplasmic reticulum (ER) within a cell and dimerizes to form a 
complex of two active TGF-β1 polypeptides enclosed in two LAPs [86]. For further 
processing, the nascent TGF-β1 is transferred from the ER to the Golgi, where it 
undergoes glycosylation/sialylation events on three asparagine residues, which are all 
present on LAP [86, 89, 90]. This processed complex is secreted from cells alone or in 
association with latent TGF-β-binding protein (LTBP) [86, 89]. Several mechanisms 
such as proteolysis, mechanical tension, or changes in pH cause LAP to release active 
TGF-β1 [89, 91]. In addition to above mechanisms, viral and bacterial sialidases can 
desialylate LAP causing LAP to change its conformation and thus releases active TGF-
β1 [22, 92-96]. 
 
The released active TGF-β1 plays an important role in maintaining homeostasis 
within the lungs [88, 91, 97]. When homeostasis is disturbed and TGF-β1 is upregulated, 




99], potentiates proliferation and differentiation of fibroblasts to myofibroblasts, and 
causes deposition of collagen in the surrounding tissue of the lungs [74, 84, 100, 101]. 
Since these are a few of many hallmarks of pulmonary fibrosis, targeting TGF-β1 can be 
a potential therapeutic strategy to control pulmonary fibrosis. This strategy has been 
previously tried, but the strategies that directly block TGF-β1 cause various side-effects, 
often interfering with the vital homeostatic functions of active TGF-β1 [102]. Thus, a 
better strategy needs to be devised to target the upregulation of TGF-β1 in a fibrotic 
lesion, rather than global TGF-β1. 
 
A possible target to attenuate fibrosis is to inhibit the fibrosis-associated TGF-β1 
activation step. Similar to viral and bacterial sialidases, we hypothesized that in a fibrotic 
lesion, mammalian sialidases can desialylate LAP, eventually releasing active TGF-β1 
and thus, upregulating the levels of TGF-β1. If successful, inhibitors of sialidases can be 
used as potential therapeutics to control sialidase-induced TGF-β1 activation and inhibit 
progression of IPF, without negatively influencing the homeostatic role of active TGF-








Fibrosis involves increasing amounts of scar tissue appearing in a tissue, but 
what drives this is unclear. In fibrotic lesions in human and mouse lungs, we found 
extensive desialylation of glycoconjugates, and upregulation of sialidases. The fibrosis-
associated cytokine TGF-β1 upregulates sialidases in human airway epithelium cells, 
lung fibroblasts, and immune system cells. Conversely, addition of sialidases to human 
peripheral blood mononuclear cells induces accumulation of extracellular TGF-β1, 
forming what appears to be a sialidase - TGF-β1 - sialidase positive feedback loop. 
Monocyte-derived cells called fibrocytes also activate fibroblasts, and we found that 
sialidases potentiate fibrocyte differentiation. A sialylated glycoprotein called serum 
amyloid P (SAP) inhibits fibrocyte differentiation, and sialidases attenuate SAP 
function. Injections of the sialidase inhibitors DANA and oseltamivir (Tamiflu) starting 
either 1 day or 10 days after bleomycin strongly attenuate pulmonary fibrosis in the 
mouse bleomycin model, and by breaking the feedback loop, cause a downregulation of 
sialidase and TGF-β1 accumulation. Together, these results suggest that a positive 
 
* Reprinted with permission from “Sialidase inhibitors attenuate pulmonary fibrosis in a mouse model” 
Karhadkar, T. R., Pilling, D., Cox, N., & Gomer, R. H., 2017. Scientific Reports, 7(1): p. 15069. Creative 






feedback loop involving sialidases potentiates fibrosis, and suggest that sialidase 
inhibitors could be useful for the treatment of fibrosis. 
 
2.2. Introduction 
Fibrosing diseases such as severe asthma, ischemic heart disease, cirrhosis of the 
liver, end stage kidney disease, and idiopathic pulmonary fibrosis (IPF) involve the 
inappropriate formation of scar tissue in an internal organ, and are associated with an 
estimated 45% of all deaths in the US [1, 2, 103, 104]. In these diseases, insults to the 
tissue, such as particulate matter or toxins in the lungs, initiate an inappropriate and 
unnecessary wound healing response, leading to organ failure and death [1, 2, 9, 105]. 
What drives the fibrosis is poorly understood. 
 
 Many secreted and cell-surface mammalian proteins are glycosylated, and many 
of the glycosylation structures have sialic acids as the monosaccharide at the distal tip or 
tips of the polysaccharide on the protein [42-44]. Some viruses, bacteria, protozoa, and 
all mammals have sialidases (also known as neuraminidases) that remove the sialic acids 
from glycoconjugates [18, 19]. Viruses such as influenza require sialidase to release the 
virus from the sialic acids on the outside of a host cell, and the sialidase inhibitors 
oseltamivir (Tamiflu) and zanamivir (Relenza) are front-line therapeutics for influenza 
[20]. The bacterial respiratory pathogen Pseudomonas aeruginosa uses a sialidase to 
colonize the lungs [21]. Mammals have four sialidases, NEU1 – NEU4. NEU1, 2, and 4 




NEU1 is in the lysosome [23-25], NEU2 is a soluble, cytosolic enzyme, and NEU4 has 2 
isoforms, one on mitochondria, and the other on intracellular membranes [26-28]. NEU3 
is in endosomes and the extracellular side of the plasma membrane, and under some 
conditions can be released from the membrane to the extracellular environment [29].  
 
 The serum glycoprotein Serum Amyloid P (which has an -(2,6)-linked terminal 
sialic acid) appears to have a calming effect on the innate immune system, and inhibits 
fibrosis in animal models and in early-stage clinical trials [14, 15, 106-111]. C-reactive 
protein (CRP) is closely related to SAP, but is not glycosylated [112]. Unlike SAP, CRP 
generally potentiates inflammation and fibrosis [113]. We mutated SAP protein surface 
amino acids that were different from CRP, and could not find a domain on the SAP 
protein surface that when mutated strongly altered SAP function [114, 115]. However, 
when SAP was desialylated with sialidase, the effects of SAP were largely abrogated 
[47]. When CRP was mutated to have a glycosylation similar to that of SAP (including a 
terminal sialic acid), the resulting CRP A32N was essentially indistinguishable from 
SAP in in vitro assays on neutrophils, monocytes, and macrophages [47]. Together, 
these results indicated that a terminal sialic acid on SAP plays a key role in its ability to 
regulate the innate immune system. 
 
 Intravenous immunoglobulin therapy is a treatment for some autoimmune 
diseases, where the intravenous immunoglobulin seems to act as an immunosuppressant 




which the glycosylation have terminal sialic acids [117]. Fractionation of 
immunoglobulins, as well as treatment of immunoglobulins with sialidase, showed that 
only immunoglobulins with terminal sialic acids act as immunosuppressants [118, 119]. 
These results support the hypothesis that a lack of glycoconjugates with sialic acids 
permits inflammation. A variety of studies indicate that sialidases potentiate 
inflammation [30, 31, 33-36, 120, 121]. Conversely, other studies indicate that 
inflammation potentiates sialidase activity, with most of the reports showing that NEU1 
is associated with inflammation [34, 53, 122-126].  
 
 In a study on patients with idiopathic pulmonary fibrosis (IPF), the 
bronchoalveolar lavage (BAL) fluid from 8 of 9 patients had a high sialidase activity, 
while the BAL fluid from 9 healthy controls showed no detectable sialidase activity [38]. 
In the 3 IPF patients where BAL was collected in subsequent years, the BAL fluid 
sialidase activity increased as the disease progressed. A recent report also found 
increased levels of NEU1 in lung fibroblasts of some but not all pulmonary fibrosis 
patients, and that adenoviral administration of NEU1 promoted bleomycin-induced lung 
inflammation and fibrosis [37]. In this report, we show that inhibiting sialidases can 








2.3. Materials and methods 
2.3.1. Cell isolation and culture 
Human peripheral blood was collected from healthy volunteers who gave written 
consent and with specific approval from the Texas A&M University human subjects 
review board. Blood collection, isolation of PBMC, sources of culture media, 
supplements, and SAP, and PBMC culture and fibrocyte counts were done as described 
previously [127, 128]. using 96 well plates (#89626 ibidi, Madison WI). 
Adenocarcinomic human alveolar basal epithelial cells (A549) (PromoCell, Heidelberg, 
Germany) were cultured in RPMI-1640 supplemented with 10% bovine calf serum 
(BCS) (Seradigm, Randor, PA), 100U/ml penicillin, 100 µg/ml streptomycin, (Lonza, 
Walkersville, MD) and 2 mM glutamine (Invitrogen, Carlsbad, CA). Human small 
airway epithelial cells (Promocell) were cultured in small airway epithelial cell medium 
(PromoCell) following the manufacturer’s protocol. Human pulmonary fibroblasts 
(PromoCell) were cultured in DMEM supplemented with 10% BCS, 100U/ml penicillin, 
100 µg/ml streptomycin, and 2 mM glutamine. Where indicated, recombinant 10 ng/ml 
human TGF-β1 (Peprotech, Rocky Hill, NJ), 200 ng/ ml recombinant human NEU1, 2, 
3, or 4 (Origene, Rockville, MD), or 2 µg/ ml human SAP (EMD Millipore, Billerica, 
MA; with the azide removed by centrifugal filters following [129]) were added to cells. 







2.3.2. Mouse model of pulmonary fibrosis 
All procedures were done with specific approval of the Texas A&M University 
institutional animal care and use committee. Mice were treated with an oropharyngeal 
aspiration of 3 U/kg bleomycin (Calbiochem, Billerica, MA) in 0.9% saline or saline 
alone as previously described [47, 111, 130, 131]. Starting either 10 days or 24 hours 
after bleomycin, when the bleomycin has been cleared from mice [132], mice were given 
daily intraperitoneal injections of 10 mg/kg DANA (N-Acetyl-2,3-dehydro-2-
deoxyneuraminic acid; EMD, Millipore) or oseltamivir (Tamiflu; Sigma, St. Louis, 
MO), both formulated as 4 mg/ ml in PBS. Mice were euthanized 21 days after 
bleomycin aspiration, and bronchoalveolar lavage (BAL) cells collected, counted, and 
cytospins were prepared as described previously [47, 111, 130, 131]. After BAL, lungs 
were inflated with and embedded in OCT compound (VWR), frozen, and stored at -80 
˚C. 6 μm sections on glass slides were air dried for 48 hours before use. BAL cytospins 
were prepared and immunochemistry were performed as described previously [47, 111, 
130] using anti- CD11b (clone M1/70 BioLegend, San Diego, CA) to detect blood and 
inflammatory macrophages or anti-CD11c (clone N418, BioLegend) to detect alveolar 
macrophages and dendritic cells with isotype-matched irrelevant antibodies (BioLegend) 
as controls. BAL fluid protein levels were measured as described previously [111]. 
 
2.3.3. Histology 
HOPE-fixed chronic obstructive pulmonary disease (COPD) and idiopathic 




Research Consortium (NIH, Bethesda, MD).  Slides were prepared for staining as 
described previously [128] and incubated with 1 g/ml biotinylated lectins SNA, PNA, 
and MAL II (Vector, Burlingame, CA) and then stained following the manufacturer’s 
instructions. Sections were also stained with 1 μg/ml of sheep polyclonal anti- 
ST3GAL2 (AF7275-SP, R&D Systems, Minneapolis, MN), anti- ST6GAL2 (AF7747-
SP, R&D Systems) or anti- ST8SIA1 (AF6716-SP, R&D Systems), 1μg/ml irrelevant 
sheep (#013-000-002, Jackson, West Grove, PA) or rabbit polyclonal antibody (#AB-
105-C, R&D Systems, Minneapolis, MN), rabbit polyclonal anti-NEU1 (TA335236, 
Origene, Rockville, MD), anti-NEU2, (TA324482, Origene,) or anti-NEU4 
(AP52856PU-N, Acris/Origene), in PBS/ 2% BSA (PBSB), or 0.5 μg/ml anti-NEU3 
(TA590228, Origene) in PBSB/ 500 mM NaCl/ 0.1% NP-40 alternative (EMD 
Millipore, Billerica, MA) for 60 minutes. Washing 3 times with PBS for 10 minutes each 
and staining were then done as previously described [127, 128], except where required 
biotinylated donkey-anti-sheep (#713-066-147, Jackson) secondary antibody was used 
for staining. Where indicated, 1 mM DANA or 1 mM Tamiflu were added to the 
antibody incubation step and the subsequent wash steps. For PBMC, the medium was 
removed and the plate was air dried for 24 hours, treated with acetone for 20 minutes, 
dried for 10 minutes, hydrated with distilled water for 5 minutes, and then PBS for 5 
minutes. For cells other than PBMC, the medium was removed and cells were fixed for 
10 minutes with 2%(w/v) paraformaldehyde (EMS, Hatfield, PA) in PBS, blocked for 10 
minutes in PBSB, and permeabilized for 8 minutes with PBS/ 0.1% (w/v) Triton X-100 




air dried, then incubated with 1 µg/ ml anti-active TGF-β1 antibodies (AB-100-NA, 
R&D Systems) in PBSB for 60 minutes. Staining of cells was then done as described 
above. After counter-staining, the plates were air-dried. 
 
2.3.4. Lung tissue lysate preparation 
Approximately half lobes of lungs frozen in OCT were cut off, thawed, washed 
once in PBS, weighed, and then frozen in liquid nitrogen. 300 μl of Pierce RIPA buffer 
(Thermo Scientific, Rockford, IL) with 1x proteases and phosphatases inhibitor cocktail 
(Cell Signaling Technology, Danvers, MA) was added per 5 mg of tissue and the tissue 
was crushed with a pestle. The mixture was then incubated on a rotator for 2 hours at 
4°C. After centrifugation at 18000 x g for 10 minutes, the supernatant was collected as 
lung tissue lysate. Total protein was measured by OD 280/ 260 with a SynergyMX plate 
reader, (BioTek, Winooski, VT) using RIPA buffer with proteases/ phosphatases 
inhibitor as a blank. 
 
2.3.5. Western blots 
For Western blots, 20 μl of BAL fluid or lysate was mixed with 4 µl 5 x Laemmli 
sample buffer and heated to 95°C for 5 minutes. Western blots were done following [14] 
with the exceptions that 4 – 20% Tris/glycine gels were from Lonza (EMD, Gibbstown, 
NJ). For analysis of lectin staining, western blots were pre-incubated with Carbo-Free 
Blocking Solution (Vector), and then incubated with biotinylated lectins diluted in the 




detected with streptavidin-HRP (BioLegend), as described previously [111]. For other 
staining, blocking was in PBS/ 2% BSA/ 5% nonfat milk. Anti-NEU 1, 2, and 4 were 
incubated at 1:1000 in PBSB. For anti-NEU3, incubations were at 1:5000 in PBS/ 2% 
BSA/ 0.1% NP-40 alternative/ 0.01% SDS. All washes were in PBS/ 0.1% (v/v) Tween 
20 (Fisher, Fair Lawn, NJ). SuperSignal West Pico Chemiluminescence Substrate 
(Thermo Scientific) was used following the manufacturer’s protocol to visualize the 
peroxidase using a ChemiDoc XRS+ System (Bio-Rad, Hercules, CA). 
 
2.3.6. Sialic acid quantitation 
Approximately 1.2 x 1.2 x 1.2 mm pieces from lungs frozen in OCT were thawed 
and washed 3 times in PBS and the lung piece was weighed. Sample hydrolysis and 
sialic acid measurement was done following [133] using resorcinol (Alfa Aesar), with 
assays done in 900 µl final volumes. Sialic acid (Vector) was used for standards. 
Absorbances were measured with a SynergyMX plate reader. Values were then 
converted to mg sialic acid / g tissue. 
 
2.3.7. TGF-β1 ELISA 
PBMC were cultured in 96 well plates at 5 x 105 cells/ml and 200 μl/ well in 
Fibrolife serum-free medium as described above. When the cells were plated, 
recombinant human sialidases were added to final concentrations of 200 ng/ml, and 




using a TGF-β1 ELISA kit, which detects total TGF-β1 (R&D Systems, Minneapolis, 
MN). 
 
2.3.8. Sialidase ELISAs 
Lung tissue lysates were diluted to 100 µg total protein/ ml in PBS. 55 µl of 
diluted lysate was added to a well of a 96-well Maxisorp immuno plate (#442404, 
Thermo Scientitic) and incubated at 4°C overnight. Serial dilutions of recombinant NEU 
1, 2, 3 and 4 (Origene) in PBS were also incubated and used for standard curves. The 
solutions were removed and the wells were blocked with 200 µl PBSB for 2 hours at 
room temperature with shaking. Anti- NEU1, 2, 3 and 4 antibodies (Origene) were then 
added in PBSB for 1 hour at room temperature following the manufacturer’s directions. 
After washing with PBSB, 1:1000 HRP-conjugated donkey-anti-rabbit IgG (Jackson) in 
PBSB was added for 1 hour. After washing, bound antibodies were detected using a 
TMB color development kit (Biolegend) and the reaction was stopped with 1 N HCl. 
Absorbances at 450nm and 550nm were measured using a SynergyMX plate reader. 
 
2.3.9. Sialidase activity assays 
Sialidase assays were done following [134, 135] with the following 
modifications. PBS was adjusted to pH 6.4 or 7.0 with 12N HCl, and BSA was added to 
a final concentration of 100 µg/ml. Recombinant human NEU 1, 2, 3, or 4 were added to 
the PBS/ BSA to 300 ng/ml. 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid 




30 minutes at room temperature, 4MU-NANA was added to the enzymes to 200 µM 
final concentration. 100 µl of the reaction was placed in the well of a 96-well plate and 
fluorescence was measured every 20 minutes at 37°C for 15 hours in a prewarmed 
SynergyMX plate reader with excitation at 360 nm and emission at 460 nm. The 
fluorescence in the absence of sialidases was subtracted from all readings. The 
fluorescence of known concentrations of 4-methylumbelliferone (Alfa Aesar) was used 
to convert fluorescence to moles of product. 
 
2.3.10. Flow cytometry 
Human pulmonary fibroblasts were cultured in the presence or absence of 10 
ng/ml TGF-β1. After 3 days, the cells were detached using Accutase cell detachment 
solution (VWR) and were fixed for 10 minutes with 2% (w/v) paraformaldehyde (EMS) 
in PBS, followed by permeabilization for 10 minutes with 0.1% (w/v) Triton X-100 
(Alfa Aesar) in PBS. Cells were then blocked for 10 minutes in PBSB. Cells were 
incubated for 60 minutes with 0.5 μg/ml anti-NEU3 or irrelevant rabbit antibody, as 
described above, the cells were washed twice with ice cold PBS. The cells were then 
incubated with 1:1000 goat anti-rabbit Alexa Fluor 647 (#A21245, Life Technologies, 
Carlsbad, CA) in PBS/ BSA and washed twice with PBS. The cells were then analyzed 
on an Accuri C6 flow cytometer (BD Bioscience) as previously described [17]. The cells 






2.3.11. Human PMN isolation and culture, and leukemia cell culture 
Peripheral blood neutrophils (PMN) were isolated using Polymorphprep 
gradients (Axis-Shield, Oslo, Norway), as previously described [136]. K562, U937, 
THP-1, NALM-6, and CHO-K1 cells (all from ATCC, Manassas, VA) and Mono Mac 6 
(DSMZ, Braunschweig, Germany) were cultured in RPMI 1640 with 10% bovine calf 
serum (BCS) (VWR-Seradigm, Radnor, PA) containing 2 mM glutamine, 100 U/ml 
penicillin, and 100 g/ml streptomycin (all from Lonza, Walkersville, MD). A549 cells, 
pulmonary fibroblasts, and PBMC were isolated and cultured as described in the main 
methods section. K562 is a chronic myeloid leukemia cell line [137], U937 is a 
lymphoma cell line [138], and THP-1 [139] and Mono Mac 6 [140] are acute myeloid 
leukemia cell lines. NALM-6 is a leukemic pre-B cell line [141]. The CHO-K1 is an 
epithelial cell line derived from the ovary of the Chinese hamster [142]. 2 x 106 cells 
were lysed in RIPA buffer (#89900, Pierce, Rockford, IL) with 1X protease and 
phosphatase inhibitors (#5872S, Cell Signaling, Danvers, MA), on ice for 2 hours. The 
lysate was clarified by centrifugation at 18,000 x g for 10 minutes at 4˚C. The 
supernatant was collected and total protein concentration was estimated for each cell 
lysate. 10 µg of protein was loaded in each well. Western blotting with sialidase 
antibodies was as described in the main methods section. Coomassie staining was done 







2.3.12. Specificity of sialidase antibodies 
800 ng of recombinant human NEU2 was added to 40 ng of anti-NEU2, or 800 
ng of recombinant human NEU3 was added to 40 ng of anti-NEU3, in a total volume of 
40 µl of PBSB. Protein: antibody mixtures were incubated at room temperature for 30 
minutes, and then aggregates were removed by centrifugation at 18,000 x g for 5 
minutes at 4 oC. Human lung sections were stained as described in the main methods 
section with anti-NEU2 or anti-NEU3 antibodies with or without pre-incubation with 
recombinant protein. 
 
2.3.13. Image quantification 
Images were converted to RGB stacks using Image J. The green channel (which 
shows the red staining) was used to adjust the intensity threshold level. The threshold 
level was kept the same for analyzing one set of images [143, 144]. The area stained as a 
percentage of the total area of the image was then determined using Image J. 
 
2.3.14. Statistical analysis 
Data were analyzed by ANOVA, with appropriate post-tests, or t-test when 









2.4.1. There is increased desialylation in fibrotic lungs 
To determine if desialylation of proteins can be observed in pulmonary fibrosis, 
we stained tissue sections with Sambucus nigra lectin (SNA) or Maackia amurensis 
lectin II (Mal II), which detect sialic acids on glycoconjugates, or peanut agglutinin 
(PNA), which detects a variety of carbohydrates if they are not sialylated [36]. 
Compared to chronic obstructive pulmonary disease (COPD) patient lungs with 
relatively normal lung function (see Table 1 for patient details), or compared to control 
mouse lungs (intratracheal saline instead of intratracheal bleomycin), fibrotic human 
lungs and fibrotic mouse lungs showed less staining for sialylated glycoconjugates, and 
increased staining for desialylated glycoconjugates (Figure 1 a-d). In the 
bronchoalveolar lavage (BAL) fluid at day 21 from bleomycin-treated mice, we 
observed increased amounts of a desialylated protein and a decreased amount of a 





Figure 1. There is decreased sialylation in pulmonary fibrosis.  
(a) Human lung sections were stained with SNA to detect sialic acids, or PNA to detect 
desialylated polysaccharides. IPF <50% FVC indicates a pulmonary fibrosis patient with 
poor lung function; COPD > 80% FEV1 indicates a chronic obstructive pulmonary 
disease patient with relatively normal lung function. Positive staining is red, with nuclei 
counterstained blue. Bar is 0.2 mm. (b) Quantification of lectin staining for human lung 
sections with ImageJ. (c) Mouse lungs at day 21 after saline or bleomycin treatment 
were stained with MAL II to detect sialic acid on glycoconjugates or with PNA to detect 
desialylated polysaccharides. Bar is 0.2 mm. (d) Quantification of lectin staining for 
mouse lung sections with ImageJ. For (b) and (d), values are mean ± SEM, n=3 or 4; ** 
indicates p < 0.005, ****p < 0.0001 (t-test). (e) BAL fluid from mice at day 21 after 
saline (S) or bleomycin were analyzed by western blotting, staining with MAL II or 
PNA. * indicates bleomycin causing decreased sialylation on a protein and arrow 
indicates bleomycin causing the gain of a desialylated protein. Molecular masses in kDa 
are at left. Images in a, c, and e are representative of 4 patients or 3 mice per group. (f) 
Total sialic acid from the day 21 lung tissue of saline- or bleomycin-treated mice. Values 














Table 1. Clinical details of human lung sections used in this study.  
FVC indicates forced vital capacity; COPD indicates chronic obstructive pulmonary 
disease; ILD indicates interstitial lung disease; Fibrosis indicates uncharacterized ILD; 
UIP indicates usual interstitial pneumonia; IPF indicates idiopathic pulmonary fibrosis; 
NSIP indicates non-specific interstitial pneumonia. Because of a limited number of lung 
tissue sections obtained from the LTRC, each type of staining was performed on a 
randomly selected set of 4 of the 5 patients from each group.  
  
Group 
FVC (mean ± 
SEM) 
Gender 
Age in years 
(mean ± SEM) 
Clinical Details 
ILD <50% 35.00 ± 3.396 
3 males; 
3 females 
46.00 ± 5.994 
n = 3 IPF /UIP, 
n = 2 fibrosis, 
n = 1 NSIP 
COPD >80% 83.80 ± 0.6633 
3 males; 
2 females 
64.80 ± 5.417 
n = 3 COPD, 
n = 2 emphysema 
t-test p < 0.0001 ns p = 0.0483  
 
Sialyltransferases catalyze the sialylation of glycoconjugates. There are 20 
identified mammalian sialyltransferases [145, 146]. Three representative 
sialyltransferases are ST3GAL2 and ST6GAL2, which sialylate oligosaccharides, and 
ST8SIA1, which sialylates gangliosides [145, 147]. In bleomycin-induced fibrotic 
lesions in mouse lungs, we observed increased levels of ST3GAL2 and ST6GAL2, and 
no change in levels of ST8SIA1 (Figure 2), suggesting that the reduced sialylation 
observed in Figure 1a-e is not due to reduced levels of these 3 sialyltransferases. Fibrotic 
mouse lungs showed normal levels of total (free + conjugated) sialic acid (Figure 1f), 
indicating that the reduced amount of sialic acid in glycoconjugates is not due to a 




                           
Figure 2. Sialyltrasferase expression in fibrotic mouse lungs. 
(a) Sections of lungs from saline- or bleomycin- treated mice were stained with 
antibodies against sialyltransferase3 (ST3GAL2), sialyltransferase6 (ST3GAL6) and 
sialyltransferase8 (ST8SIA1). All images are representative of 3 mice per group. Bar is 
0.2 mm. Quantification of staining for ST3GAL2 (b), ST3GAL6 (c), and ST8SIA1 (d) 
with ImageJ. Values in b – d are mean ± SEM, n = 3 mice per group; * indicates p < 
0.05, ***p < 0.001 (t-test). 
 
2.4.2. Sialidases are upregulated in fibrotic lungs 
In addition to the observation that there is sialidase activity in the BAL fluid 
from patients with IPF [38], the above results suggest the possibility that there may be 
increased sialidase protein in fibrotic lungs. To examine this, we stained lung sections 
from IPF patients and COPD patients with antibodies against the four human sialidases. 
The antibodies were made against domains of the sialidases that are different from each 
other, do not bind the other sialidases (Figure 3), and stain bands on western blots of 





                                     
Figure 3. The specificity of anti-sialidase antibodies.  
Western blots of recombinant (r) c-Myc tagged human sialidase proteins were stained 
with the indicated antibodies. Positions of molecular mass markers are at left. All four 
proteins were stained with anti-c-Myc antibodies (top panel). Each sialidase was 
detected by its corresponding antibody (bottom 4 panels). The antibody for a particular 
sialidase did not cross react with sialidases other than its target. All images are 
representative of three independent experiments. 
 
The COPD lungs showed low levels of the four human sialidases (Figure 4a). 
Two of three IPF patient lungs showed no significant staining for sialidase 1 (NEU1) 
while one IPF patient did have increased levels of NEU1 staining. Compared to the 
COPD patients, the ILD patient lungs had increased levels of NEU2, NEU3, and NEU4 





Figure 4. Some sialidases are upregulated in lung fibrosis.  
Human (a) and mouse (b) lung sections as in Figure 1 were stained for the indicated 
sialidases. Outside image bars are at 0.2 mm. Inset in a and b are higher magnification 
images of the IPF (a) or bleomycin (b) lungs; bars are 0.1 mm. All images are 
representative of 4 patients or 3 mice per group. Quantification of sialidase staining for 
human (c) and mouse (d) lung sections with ImageJ. Values are mean ± SEM, n=3 or 4; 
* indicates p < 0.05, **** p < 0.0001 (t-test). (e) BAL fluid from mice at day 21 after 
saline or bleomycin were stained for sialidase3. 1, 2, and 3 refer to different individual 
mice. Positive staining appears black. Molecular masses in kDa are at left. (f) 
Quantification of NEU3 in (e) western blot, values expressed in percent relative density 
of black bands. Values are mean ± SEM, n=3 or 4; * indicates p < 0.05 (t-test). 
 
we pre-incubated the NEU2 and NEU3 antibodies with recombinant NEU2 or NEU3 




tissue (Figure 5). Mice treated with oropharyngeal bleomycin develop fibrotic lesions in 
the lungs at day 21 [150]. Mice treated with oropharyngeal saline as a control had low 
levels of all four mouse sialidases in their lungs (Figure 4b). Compared to the controls, 
bleomycin-treated mice had fibrotic lesions and increased levels of NEU1, NEU2, and 
NEU3, but no increase in NEU4 (Figure 4 b and d). Higher magnification images 
showed patchy distributions of the upregulated sialidases in fibrotic lesions (inset in 
Figure 4 a and b). In the BAL fluid from mice with bleomycin-induced lung fibrosis, 
NEU1, 2, and 4 were not detected, even on over-exposed western blots (Figure 6), while 
NEU3 was upregulated compared to the BAL fluid from control mice (Figure 4 e and f). 
For unknown reasons, one bleomycin-treated mouse also showed anti-NEU3 staining of 
a band with an apparent molecular mass higher than NEU3 (Figure 4 e) Together, these 





Figure 5. Specificity of sialidase antibodies.  
To confirm the specificity of the NEU2 and NEU3antibodies, we pre-incubated the 
NEU2 and NEU3 antibodies with recombinant NEU2 or NEU3 respectively. Fibrotic 
human lung sections were then stained as described in Figure 2a. Bar is 0.2 mm. Pre-
incubation of sialidase antibodies with recombinant protein abrogated staining, compared 




Figure 6. Sialidases 1, 2, and 4 are not detected in mouse BAL fluid.  
BAL fluid from mice at day 21 after saline or bleomycin were stained for the indicated 
sialidases. 1, 2, and 3 refer to different individual mice. Positive staining would appear 
black. Molecular masses in kDa are at left. To determine if low levels of the sialidases 
were present, we over exposed the western blots. This reveal “negative” staining of 
albumin, especially in the BAL from bleomycin treated mice. 
 
To further test the hypothesis that sialidases are upregulated in the fibrotic lungs, 
we prepared lung tissue lysates from saline and bleomycin treated mice. Total protein 
concentration and concentrations of the sialidases were measured in the lysates. 
Compared to saline controls, the bleomycin-treated mice had significantly higher levels 
of NEU1, NEU2 and NEU3, but not NEU4, in their lung lysates (Figure 7 a-d). In 
addition, on Western blots, compared to saline, bleomycin-treated mouse lung tissue 
lysates had significantly upregulated levels of NEU3 (Figure 7 e and f). Together, these 





Figure 7. Detection of upregulated sialidases in bleomycin-treated mouse lung    
tissue lysates. 
Lysates from the indicated treatment groups were assayed for total protein and assayed 
by ELISA for (a) NEU1, (b) NEU2, (c) NEU3, and (d) NEU4. (e) Western blot of lung 
tissue lysate from a saline (sal) and a bleomycin (bleo) treated mouse stained for NEU3 
(upper panel); aliquots of the samples were run on an SDS-PAGE gel and stained with 
Coomassie brilliant blue (CB) (lower panel). The positions of molecular mass standards 
in kDa are at left. Images are representative of 3 pairs of mice. (f) Quantification of 
western blots. In (a-f) values are mean ± SEM, n=3; * indicates p < 0.05 (t-test). 
 
2.4.3. The pro-fibrotic cytokine TGF-β1 upregulates sialidases in cells 
TGF-β1 is strongly associated with fibrosis, and is the most potent, and well-
characterized, inducer of fibrosis [101, 103]. As the main cell types involved in lung 
fibrosis are epithelial cells, fibroblasts, and immune cells, we cultured the human 
alveolar basal epithelial adenocarcinoma cell line A549, human small airway epithelial 
cells, human pulmonary fibroblasts, and human immune cells (PBMC) with or without 




experiments [100, 105, 151, 152] for five days. After five days, the cells were stained 
































Figure 8. TGF-β1 increases sialidase expression in cultured cells.  
(a-d) The indicated human cell types were cultured in the presence or absence of 10 
ng/ml TGF-β1 for 3 days and then stained for the indicated sialidases. All images are 







sialidases. TGF-β1 caused A549 cells to undergo a characteristic change in morphology 
[153] and to increase levels of NEU3 and the percent of cells positive for Neu3 (Figure 8 
a and Figure 9 a). TGF-β1 also caused human small airway epithelial cells to increase  
levels of NEU3, the percent of cells positive for Neu3 and slightly increased levels of 
NEU1 (Figure 8b and Figure 9 b). As previously observed, TGF-β1 increased the 
proliferation of human pulmonary fibroblasts [154], and caused these cells to increase 
levels of NEU3 (Figure 8c and Figure 10). TGF-β1 increased levels of NEU2 and NEU3 
in some cells in cultures of human PBMC (Figure 8 d and Figure 9 c). 
 
Figure 10. TGF-β1 increases NEU3 expression in human pulmonary fibroblasts.   
Human pulmonary fibroblasts were incubated with and without TGF-β1 as in Figure 8c, 
and analyzed for anti- NEU3 staining by flow cytometry. (a) Flow cytometry plot 
representative of 3 separate experiments. M1 indicates gate of positively stained cells 
used for panel c. (b) Median fluorescence intensity in arbitrary units. (c) Percentage of 
positively stained cells. Values in b and c are mean ± SEM, n = 3. ** p < 0.01 (t-test). 
Figure 9. Quantification of TGF-β1 increased sialidase expression.  
(a) A549 cells, (b) lung epithelial cells, and (c) PBMC were incubated with and 
without TGF-β1 as in Figure 4c, and analyzed for sialidase expression. Values are 
mean ± SEM of the percent positive cells, n = 3. The absence of an error bar indicates 





2.4.4. Sialidases show some activity at neutral pH 
The enzymatic activity of the four human sialidases has been characterized [155, 
156], with >50% activity between pH of 3.5 to 5.5, although NEU4 is still ~50% active 
at pH 7.4 [155, 157]. To determine if sialidases might have enzymatic activity at the pH 
of the extracellular environment, we assayed recombinant human sialidases at pH 6.4, 
approximately corresponding to the extracellular pH that might occur in a fibrotic tissue 
[158], and at pH 7.0, approximately corresponding to a normal extracellular pH [158]. 
All four recombinant sialidases showed activity at pH 6.4 and pH 7.0 (Table 2), 
indicating that sialidases could be active in an extracellular environment.  
 
Table 2. Sialidases have activity at neutral pH.  
Recombinant human sialidases were assayed for activity at pH 6.4 and pH 7.0. Values 
are mean ± SEM, n=3.  
Activity, μmole / min / mg protein 
Sialidase pH 6.4 pH 7.0 
NEU1 12.8 ± 1.3 7.2 ± 0.9 
NEU2 16.4 ± 1.2 8.9 ± 1.2 
NEU3 15.2 ± 1.0 8.3 ± 1.2 
NEU4 3.8 ± 0.8 2.6 ± 0.9 
 
2.4.5. NEU2 and NEU3 upregulate the intracellular and extracellular accumulation 
of TGF-β1 by PBMC 
To determine if sialidases might cause cells to accumulate intracellular and 
extracellular TGF-β1, cells were cultured with sialidases. The levels of active TGF-β1 in 
or on the cells was detected by staining with an antibody against active TGF-β1 (Figure 




extracellular accumulation of total TGF-β1 (Figure 11 d). When added to human PBMC, 
human NEU1 and NEU4 had no significant effect on the accumulation of TGF-β1, while 
NEU2 and NEU3 increased both cell-associated and extracellular TGF-β1 (Figure 11 a-
d). The addition of the sialidase inhibitors DANA or Tamiflu blocked the effects of 
NEU2 and NEU3 on extracellular TGF-β1 (Figure 11 d), indicating that the effects of 
NEU2 and NEU3 are due to their sialidase activities. These data suggest that sialidases 
might be able to potentiate fibrosis by increasing levels of extracellular TGF-β1. 
 
2.4.6. NEU2, NEU3, and NEU4 counteract the ability of SAP to inhibit        
fibrocyte differentiation 
In support of the hypothesis that sialidases potentiate fibrosis, we observed that 
recombinant human NEU2, 3 and 4, when added to human PBMC, potentiate fibrocyte 
differentiation and counteract the ability of human SAP to inhibit fibrocyte 
differentiation (Figure 11 e). NEU1 however did not potentiate fibrocyte differentiation 
or counteract SAP. 
 
2.4.7. Sialidase inhibitors decrease fibrosis 
The sialidase inhibitor DANA inhibits all mammalian sialidases [159]. Although 
Tamiflu is a poor inhibitor of human sialidases, it is a potent inhibitor of murine 
sialidases, and inhibits LPS-induced mouse macrophage sialidase activity with an IC50 



















Figure 11. Some sialidases upregulate TGF-β1 and counteract the ability of SAP to 
inhibit fibrocyte differentiation.  
(a) Human PBMC were incubated with or without recombinant human sialidases for five 
days, then air dried and stained for TGF-β1. All images are representative of 3 
independent experiments. Positive staining appears pink and counter staining is blue. Bar 
is 0.1 mm. (b) After staining, positively stained macrophages were counted and 
expressed as a percent of total cells. Values are mean ± SEM, n=3. * p < 0.05, ** p < 
0.005 (t-test). (c) Quantification of staining intensity by ImageJ. Values are mean ± 
SEM, n=3. * p < 0.05 (t-test). (d) Human PBMC were incubated with or without 
recombinant human sialidases, DANA, or Tamiflu for 5 days in serum-free medium. The 
conditioned media were analyzed by ELISA for total TGF-β1. Values are mean ± SEM, 
n=7. * p < 0.05, ** p < 0.01 (t tests). (e) Human PBMC were incubated in serum-free 
medium in the presence or absence of recombinant human sialidase or 2 µg/ ml human 
SAP. After 5 days, fibrocytes were counted. Values are mean ± SEM, n=3. * p < 0.05 (1-
way ANOVA, Dunnett’s test). No fibrocytes were detected in the cultures with SAP and 
no sialidase or SAP and NEU1. 
 
were treated with oropharyngeal bleomycin to induce symptoms of pulmonary 
fibrosis [150] and then starting 10 days after bleomycin (when fibrosis has begun in this 
model [150]), mice were given daily intraperitoneal injections of 10 mg/kg DANA or 10 
mg/kg Tamiflu. Both inhibitors are quite polar, and thus probably remain in the 




would then be ~3 µM. The DANA and Tamiflu treatments did not significantly affect 
mouse weights (Figure 12). At day 21, the DANA and Tamiflu treatments decreased the 
bleomycin-induced fibrosis, (Figure 13 a-c) and also counteracted the bleomycin-












Figure 12. DANA and Tamiflu have no significant effect on the weight of   
bleomycin-treated mice. 
Weights of mice used for the data in Figure 6 were recorded daily starting on day 10 
(when mice were randomly assigned to the treatment groups). Values are mean ± SEM, 
n = 3 mice per group. 
 
Unlike SAP treatment [111], Tamiflu treatment resulted in less protein in the BAL 
(Figure 13 e), suggesting that Tamiflu may inhibit edema or epithelial barrier destruction 
following bleomycin instillation. The DANA and Tamiflu treatments also reduced 
staining for TGF-β1 (Figure 14). Similar results were observed with DANA and Tamiflu 





Figure 13. Inhibition of sialidases starting at day 10 after bleomycin attenuates 
fibrosis. 
(a) Sections of lung tissue from mice treated with bleomycin or saline, and then injected 
daily with saline, DANA, or Tamiflu starting at day 10 after bleomycin, and then 
euthanized at day 21, were stained for collagen with Sirus Red. Bar is 0.2 mm. All 
images are representative of 3 mice per group. (b) Quantification of staining with 
ImageJ. The percentage of area stained was quantified as a percentage of the total area of 
the lung. (c,d) The total number of cells and number of CD11b+ cells in the BAL. (e) 
Total protein in the BAL. For B-E, values are mean ± SEM, n = 3 mice per group. * 
indicates p < 0.05, **p < 0.01 (1-way ANOVA, Tukey’s test). In B and D, the 
differences between Saline, Bleo+DANA, and Bleo+Tamiflu were not significant. 
 
significantly reduced BAL protein content [160]. Together, these results suggest that 





Figure 14. Sialidase inhibitors reduces TGF-β1 staining.  
(a) Sections of lung tissue from mice treated with bleomycin or saline, and then injected 
daily with saline, DANA, or Tamiflu starting at day 10 after bleomycin, and then 
euthanized at day 21, were stained for TGF-β1. All images are representative of 3 mice 
per group. (b) Quantification of staining intensity with ImageJ. Values are mean ± SEM, 
n = 3 mice per group. * indicates p < 0.05 (t-test). 
 
In further support of the hypothesis that inhibiting sialidases can break a sialidase 
→ fibrosis → sialidase positive feedback loop, we observed that DANA treatment 
starting 10 days after bleomycin decreased NEU1, NEU2 and NEU3 staining at 21 days 
[160]. When staining of serial sections of fibrotic lesions with anti-NEU2 was done with 
DANA or Tamiflu present in the antibody and wash solutions, staining was still 
observed [160], indicating that residual DANA or Tamiflu that might have been present 
in the DANA or Tamiflu-treated lungs was not blocking the anti-NEU2 staining. Similar 
results were observed for DANA and Tamiflu not inhibiting NEU3 staining [160]. 
Together, these results indicate that DANA and Tamiflu treatments reduce fibrosis, and 
appear to break the sialidase → fibrosis → sialidase positive feedback loop as evidenced 





In this report, we observe desialylation of glycoconjugates in human and mouse 
pulmonary fibrosis, which is likely due to the observed elevated levels of sialidases. We 
found what may be a positive feedback loop, with high levels of sialidases increasing 
extracellular TGF-1 accumulation by human PBMC, and TGF-1 increasing sialidases 
in human lung epithelial cells, fibroblasts, and PBMC. In support of the hypothesis that 
sialidases play a role in fibrosis, two different sialidase inhibitors strongly decreased 
fibrosis in the mouse bleomycin model of pulmonary fibrosis.  
 
A recent report found increased levels of NEU1 in lung fibroblasts of some but 
not all pulmonary fibrosis patients [37]. We also observed increased NEU1 in mouse 
pulmonary fibrosis, and in one of three ILD patients. We also observed increased levels 
of NEU2 and NEU3 in mouse and pulmonary fibrosis, and observed that TGF-β1 can 
increase NEU2 and NEU3 in PBMC, and NEU3 in epithelial cells and fibroblasts. Other 
workers found elevated levels of sialidase activity in the BAL fluid from IPF patients 
[38], and we detected upregulated levels of NEU3 in the BAL fluids from mice with 
bleomycin-induced pulmonary fibrosis. Compared to healthy individuals, in IPF patients 
there are no significant increases in the mRNAs encoding NEU1 – 4 [161]. This suggests 
that, like many other proteins that are upregulated post-transcriptionally by TGF-β1 
[162], sialidases may be upregulated post-transcriptionally by TGF-β1. In addition, 
sialidase protein production, secretion, and activity, can also be regulated by proteins 




NEU1 [23, 26, 163]. Together, these results suggest that post-transcriptional 
upregulation of multiple sialidases may contribute to fibrosis. 
 
Desialylation of SAP blocks all of its known activities on cells [47], and NEU2, 
3 and 4 counteract SAP. These results suggest the possibility that in addition to sialidase 
upregulating TGF-β1 accumulation by immune cells, sialidase may potentiate fibrosis by 
desialylating SAP and inhibiting its activity, and that SAP is a key sentinel monitoring 
extracellular sialidase activity. The only known variation in serum SAP from healthy 
humans, other than concentration, is a small percentage of desialylated SAP [164-166]. 
Desialylated SAP is rapidly cleared from the circulation [165], and an intriguing 
possibility is that the low serum SAP levels observed in patients with IPF [108, 167], 
myelofibrosis [168], and non-alcoholic fatty liver disease [109] may be due to increased 
sialidase activity associated with fibrosis. Some tumors have elevated levels of NEU3 
[156]. The high levels of NEU3 inhibit apoptosis, and intriguingly decreased apoptosis is 
a hallmark of fibrotic fibroblasts [169]. In tumors, high levels of NEU3 increase 
extracellular interleukin-6 (IL-6) [156], and IL-6 is also associated with fibrosis [170]. 
Sialidases may thus potentiate fibrosis by a combination of increasing TGF-β1, causing 
clearance of SAP, inhibiting apoptosis, and increasing IL-6. 
 
 Since fibrosis has very close similarities to the formation of scar tissue in a 
wound, a possible explanation for the fibrosis → sialidase → fibrosis positive feedback 




control systems engineering, a small amount of positive feedback, as long as the gain of 
the system is less than 1 (i.e. a small amount of noise does not cause the system to 
oscillate or swing to one extreme or another), can dramatically increase both the 
sensitivity and the response time of a system [171]. If this feedback loop has a gain of 
less than 1, it would allow a faster response to wounds and faster wound healing. We 
think that in some individuals, or in some perturbed situations, the fibrosis → sialidase 









Pulmonary fibrosis involves the formation of inappropriate scar tissue in the 
lungs, but what drives fibrosis is unclear. Sialidases (also called neuraminidases) cleave 
terminal sialic acids from glycoconjugates. In humans and mice, pulmonary fibrosis is 
associated with desialylation of glycoconjugates and upregulation of sialidases. Of the 
four mammalian sialidases, we previously detected only NEU3 in the bronchoalveolar 
lavage fluid from mice with bleomycin-induced pulmonary fibrosis. In this report, we 
show that NEU3 upregulates extracellular accumulation of the pro-fibrotic cytokines IL-
6 and IL-1β, and IL-6 upregulates NEU3, in human peripheral blood mononuclear cells, 
suggesting that NEU3 may be part of a positive feedback loop potentiating fibrosis. To 
further elucidate the role of NEU3 in fibrosis, we used bleomycin to induce lung fibrosis 
in wild-type C57BL/6 and Neu3-/- mice. At 21 days after bleomycin, compared to male 
and female C57BL/6 mice, male and female Neu3-/- mice had significantly less 
inflammation, less upregulation of other sialidases and the profibrotic cytokine active 
TGF-β1, and less fibrosis in the lungs. Our results suggest that NEU3 participates in 
fibrosis, and that NEU3 could be a target to develop treatments for fibrosis. 
 
† Reprinted with permission from “Attenuated pulmonary fibrosis in sialidase-3 knockout (Neu3-/-)mice.” 
Karhadkar, T. R., Chen, W., & Gomer, R. H., 2020. American Journal of Physiology-Lung Cellular and 






Fibrosis involve the inappropriate formation of scar tissue in an internal organ, 
and 45% of deaths in the US are associated with fibrosis [2, 9, 10]. Pulmonary fibrosis is 
the generic term for a broad category of lung diseases that includes idiopathic pulmonary 
fibrosis (IPF). IPF is a chronic and fatal disease characterized by fibrosis of lungs with a 
median survival of 3-5 years after initial diagnosis [10, 12]. IPF affects ~3 million 
people worldwide, with an incidence of 1 in 400 in the elderly [10, 12]. 
 
Sialic acid is a monosaccharide frequently located at the terminal positions of 
glycoconjugates [42, 44].  Sialidases, which are also called neuraminidases, remove the 
terminal sialic acid from these glycoconjugates [18, 19]. There are four known 
mammalian sialidases, NEU1, NEU2, NEU3, and NEU4, and these have different 
subcellular localizations and substrate specificities [52]. Sialidase activity was detected 
in the bronchoalveolar lavage (BAL) fluid from 8 of 9 pulmonary fibrosis patients, but 
no sialidase activity was detected in the BAL fluid from healthy controls [38]. There is 
upregulation of the sialidase NEU1 in pulmonary fibrosis [37], and in addition to 
upregulation of NEU1, we detected desialylation of glycoconjugates and upregulation of 
NEU2 and NEU3 in fibrotic lesions in human and mouse lungs [160]. NEU3, but not 
NEU1, NEU2, or NEU4 was detected in the BAL fluid from mice with bleomycin 
induced pulmonary fibrosis.; no detectable sialidases were in the BAL fluid from control 
mice [160]. When added to human immune cells, NEU2 and NEU3 upregulated the 




TGF-β1 added to human lung fibroblasts, lung epithelial cells, and peripheral blood 
mononuclear cells (PBMC) upregulated NEU3 expression [160]. Serum amyloid P 
(SAP) is a serum protein that inhibits fibrosis in humans, mice, and rats [172], while 
fibrocytes are monocyte derived cells that participate in fibrosis [64, 173, 174]. NEU2, 
3, and 4 counteract SAP function and potentiate fibrocyte differentiation in the presence 
or absence of SAP [160]. The small molecules DANA and Oseltamivir are sialidase 
inhibitors. We found that DANA and Oseltamivir reduce bleomycin-induced pulmonary 
fibrosis in mice, even when treatment was initiated at day 10 after bleomycin [160]. 
These results suggested that sialidases are involved in pulmonary fibrosis. 
 
Many of the effects of sialidases in fibrosis, such as the sialidase activity in 
pulmonary fibrosis patient BAL fluid [38], appear to be in the extracellular environment. 
NEU1, NEU2, and NEU4 are localized inside cells [52], while NEU3 is localized on the 
extracellular side of the plasma membrane [52, 175, 176]. NEU3 may thus be a key 
sialidase involved in fibrosis. NEU3 is upregulated in colon [55], renal [56], ovarian 
[57], and prostate cancers [58]. Overexpression of NEU3 in human colon cancer cells 
promotes cell proliferation and adhesion, suggesting that the high levels of NEU3 
observed in some tumors may potentiate the tumor [177]. To elucidate the function of 
NEU3, NEU3 deficient (Neu3-/-) mice were generated in a C57BL/6 background by 
disrupting exon 3 of Neu3 [178]. Compared to control C57Bl/6 mice, Neu3-/- mice have 
normal lifespans, appearance, fertility, ganglioside composition of tissues, and histology 




similar to parental mice [178]. In support of the role of NEU3 in cancer, Neu3-/- mice 
have a reduced incidence of colitis-associated colon cancer [178].  
 
To elucidate the role of NEU3 in pulmonary fibrosis, in this report we used 
bleomycin to induce pulmonary fibrosis in wildtype and Neu3-/- mice, and find that 
Neu3-/- mice have strongly attenuated inflammation and fibrosis in response to 
bleomycin, suggesting that NEU3 plays a major role in bleomycin-induced pulmonary 
fibrosis in mice. 
 
3.3. Materials and methods 
3.3.1. Mouse strains 
A breeding colony of C57BL/6 background Neu3-/- mice strain B6.129-
Neu3tm1Yamk [178], originally from Kazunori Yamaguchi from Miyagi Cancer Center 
Research Institute, Natori, Japan, was established by Dr. Jamey Marth at UC Santa 
Barbara, and some of the mice from this colony were sent to Texas A&M. Sex- and age-
matched C57BL/6 wild type mice were from Jackson Laboratories (Bar Harbor, ME). 
Tailsnip DNA was collected as described previously [179], and PCR was used to check 
the Neu3 gene disruption and the presence of the Neu1, Neu2, and Neu4  genes using the 
primers [180]. As a control, the presence of the β-actin gene in the tailsnip DNA samples 
was checked by PCR using the primers [180]. Wild-type C57BL/6 mice showed a Neu3 
PCR product that was absent in Neu3-/- mice, and actin controls showed that template 




animals were carried out in accordance with National Institutes of Health guidelines. All 
experimental protocols were approved by the Texas A&M University Institutional 
Animal Care and Use Committee. 
 
Figure 15. Neu3-/- mice genotyping.  
(a) Tailsnip DNA was prepared from wildtype C57BL/6 (+/+) and Neu3-/- (-/-) mice, and 
PCR was used to check for the presence of a 2.1 kBP piece of the Neu3 gene. Molecular 
mass markers in BP are at left. (b) PCR was used to check for the presence of a 310 BP 
fragment of the β-actin gene in the DNA samples. 
 
3.3.2. Mouse model of pulmonary fibrosis 
Mice were used in three separate groups to achieve 3 male and 3 female Neu3-/- 
mice treated with saline, 3 male and 3 female Neu3-/- mice treated with bleomycin, 3 
male and 3 females C57BL/6 mice treated with saline, and 5 male and 4 female 
C57BL/6 mice treated with bleomycin. An additional female C57BL/6 mouse treated 
with bleomycin developed signs of distress on day 10 and was immediately sacrificed 
and not included in the study; an autopsy showed that this mouse had a blocked 




the Neu3-/- bleomycin group and one 18-week old female in the Neu3-/- saline group. In 
all of the assays, the 18-week old females did not show any obvious differences 
compared to the other Neu3-/- females. All other mice survived until sacrifice at day 21, 
and were used in the study. The mice were sedated for 60 seconds with 4% isoflurane in 
oxygen and then treated with an oropharyngeal aspiration of 50 μl of 3 U/kg bleomycin 
(Calbiochem, Billerica, MA) in 0.9% saline or saline alone as previously described [47, 
111, 130, 131]. Mice were sacrificed 21 days after bleomycin aspiration, and 
bronchoalveolar lavage fluid (BAL) and blood were collected. The liver, heart, kidneys, 
and spleen were removed and weighed. After BAL collection, lungs were inflated at 
equal pressures with, and embedded in, OCT compound (VWR, Radnor, PA), frozen, 
and stored at -80˚C. The cells collected from BAL were counted, and cytospins were 
prepared as previously described [47, 111, 130, 131]. Blood was clarified by 
centrifugation at 10,000 x g for 5 minutes to obtain serum, which was stored at -80 ˚C. 
 
3.3.3. Histology 
10 μm lung cryosections on glass slides and BAL cytospins were air dried for 48 
hours before use. Lung cryosections or BAL cytospins were fixed in fresh acetone for 20 
minutes at room temperature and then rehydrated in water for 5 minutes and then PBS 
for 5 minutes. Slides were blocked with PBS containing 2% BSA (PBSB) for 30 minutes 
and further processed as described previously [47, 160]. Slides with cryosections or 
BAL cytospins were incubated with 5 µg/ml anti- CD11b (clone M1/70 BioLegend, San 




BioLegend) to detect resident alveolar macrophages and dendritic cells, anti-CD45 
(clone 30-F11, BioLegend) to detect all leukocytes, and anti-Ly6G (1A8, BioLegend) or 
anti-Ly6C (HK1.4, BioLegend) to detect macrophage subsets and neutrophils which 
have been reported to be upregulated in the bleomycin induced pulmonary fibrosis 
mouse model [47, 111, 127, 128, 160]. Slides with BAL cytospins were also incubated 
with 5 ug/ml anti-CD3 (clone 17A2, #100202, Biolegend) to detect T cells or 5 ug/ml 
anti-CD19 (90176T, Cell Signaling Technology, Danvers, MA) to detect B cells. Some 
lung section slides were stained with 1 µg/ml rabbit polyclonal anti-NEU1 (TA335236, 
Origene, Rockville, MD), anti-NEU2, (TA324482, Origene,), anti-NEU4 (AP52856PU-
N, Acris/Origene), or anti-TGF-β1 (AB-100-NA, R&D systems, Minneapolis, MN) in 
PBSB, or 0.5 μg/ml anti-NEU3 (TA590228, Origene) in PBSB/ 500 mM NaCl/ 0.1% 
NP-40 alternative (EMD Millipore, Billerica, MA) for 60 minutes. Isotype-matched 
mouse irrelevant antibodies (BioLegend) were used as controls. After washing 3 times 
with PBS for 10 minutes each, the slides were incubated with 1:500 biotinylated donkey-
anti-rabbit (#711-066-152, Jackson ImmunoResearch Laboratories, West Grove, PA) or 
biotinylated donkey-anti-goat (#713-066-147, Jackson) secondary antibodies and 
staining was then done as previously described [127, 128]. Lung sections were stained 
with hematoxylin and eosin or Sirius red to detect collagen as previously described [15]. 
Light microscopy images were taken using a 4x lens on a Microphot-FX microscope 
(Nikon, Melville, NY) or 10x and 40x lenses on a DM6B microscope (Leica, Buffalo 
Grove, IL). Polarized light images were also taken on the DM6B microscope. Images of 




for size bars. Fields were chosen randomly and counted blindly. Image quantification 
was done as previously described [160]. Images were converted to RGB stacks using 
Image J. The green channel (which shows the red staining) was used to adjust the 
intensity threshold level. The threshold level was kept the same for analyzing a set of 
images. The total area of the image, and the area stained as a percentage of the total area 
of the image, were then determined using Image J.  
 
3.3.4. Immunofluorescence staining 
Glass slides with 10 μm lung cryosections were fixed in acetone for 20 minutes 
at room temperature and then rehydrated in water for 5 minutes and then PBS for 5 
minutes. Slides were blocked with PBSB for 30 minutes. After blocking, the slides were 
incubated with 1 μg/ml rabbit anti-NEU3 (21630002, Novus Biologicals LLC, 
Centennial, CO), 5 μg/ml rat anti- mouse CD11b (BioLegend), rat anti-mouse CD11c 
(BioLegend), rat anti- mouse CD31 (BioLegend), rat anti-mouse Ly6c (BioLegend), rat 
anti-αSMA (NB300-978, Novus Biologicals LLC) or rat anti-EpCAM (BioLegend) in 
PBSB containing 500 mM NaCl at 4℃ overnight. After washing 3 times with PBS for 
10 minutes, slides were incubated with 2 μg/ml donkey-anti-rat Rhodamine-Red-X 
(#712-296-153, Jackson) or donkey-anti-rabbit Alexa Fluor 488 (#711-546-152, 
Jackson) in PBSB for 30 minutes at room temperature. After washing 3 times with PBS, 
slides were mounted with DAPI containing mounting media (H-1500, Vector 
Laboratories, Burlingame, CA). The slides were kept in the dark at 4°C for 1 hour to 




Ti2 microscope. The number of cells stained for NEU3 (green) but not the other cell 
marker (red), the number stained for both NEU3 and the other cell marker, and the 
number stained for the other cell marker but not NEU3 were counted in 3 randomly 
chosen fields of view. The percentage of cells of a specific type (stained red) which co-
stained for NEU3 was calculated. 
 
3.3.5. Differential cell staining 
BAL cytospins were fixed and treated with Wright-Giemsa stain (#08711, 
Polysciences, Inc. Warrington, PA) following the manufacturer’s instructions. 200 cells 
per mouse were examined and scored for cell type following the manufacturer’s 
instructions. 
 
3.3.6. Alveolar wall area fraction 
Because alveolar wall thickness increases due to fibrosis or interstitial oedema 
[181], the alveolar wall area fraction was determined from the hematoxylin and eosin 
stained lung slides. The quantification of alveolar wall area fraction was performed as 
described previously [181, 182], where 5 randomly selected 1.19 x 0.92 mm fields 
without blood vessels or airways were imaged using a 4× objective on a Microphot-FX 
microscope. ImageJ was used to measure the area of all stained tissue as a percentage of 
the total image area. The alveolar wall area fraction value for 5 fields was averaged for 





3.3.7. 13-plex mouse inflammation panel analysis 
BAL, and serum samples collected at day 21 post bleomycin aspiration were 
processed following the manufacturer’s protocol (#740150, LEGENDplex™ Mouse 
Inflammation Panel (13-plex), Biolegend) for simultaneous quantification of 13 mouse 
cytokines using an Accuri C6 (BD Bioscience, Franklin Lakes, NJ) flow cytometer. 
 
3.3.8. Western blots 
For Western blots, 20 μl of BAL fluid was mixed with 4 µl 5x Laemmli sample 
buffer and heated to 95°C for 5 minutes. Western blots were done following [14, 160] 
with the exceptions that 4 - 20% Tris/glycine Mini-Protean TGX gels were used (#456-
1096, Bio-Rad, Hercules, CA). Equal volumes (1 µl) of BAL fluid were loaded on gels. 
50 – 140 ng of recombinant human NEU1 (TP300386, Origene), NEU2 (TP319858, 
Origene), NEU3 (TP316537, Origene), NEU4 (TP303948, Origene), or active-TGF-β1 
(100-21-10UG, PeproTech, Rocky Hill, NJ) were loaded on gels as positive controls. 0.1 
– 1.0 μg of human serum albumin (A1653-1G, Sigma-Aldrich) was loaded on other gels 
as a positive control. For western blot staining, blocking was in PBS/ 2% BSA/ 5% 
nonfat milk. Blots were incubated with anti-NEU 1, 2, and 4 antibodies (Origene) at 
1:1000 in PBSB for 60 minutes at room temperature as described previously [160]. For 
anti-NEU3, incubations were at 1:5000 in PBS/ 2% BSA/ 0.1% NP-40 alternative/ 
0.01% SDS for 60 minutes at room temperature as described previously [160]. 1:5000 
peroxidase-conjugated donkey-anti-rabbit (#711-036-152, Jackson) was used as 




Lawn, NJ). For western blot detection of  active TGF-β1, non-reducing/ no SDS 
conditions to prepare samples and electrophoresis were used [183]. For western blot 
staining of albumin, blocking was in 5% nonfat milk in immunoblot buffer (25mM Tris, 
0.15M NaCl, and 0.1% Triton X-100). 1:50,000 anti-albumin antibody (AF3329, R&D 
systems) incubations were in immunoblot buffer. Western blots stained for albumin were 
washed in Tris-buffered Saline (TBS)/ 0.1% (v/v) Tween 20 (TBST).  Peroxidase-
conjugated donkey anti-rabbit (Jackson), and biotin-conjugated donkey anti-goat 
(Jackson) were used as secondary antibodies. SuperSignal West Pico 
Chemiluminescence Substrate (Thermo Scientific, Rockford, IL) was used following the 
manufacturer’s protocol to visualize the peroxidase using a ChemiDoc XRS+ System 
(Bio-Rad). Some blots were incubated with 0.1% Ponceau stain (Matheson, Norwood, 
OH) in 5% acetic acid for 30 minutes and washed 2 times with PBST for 10 minutes 
each. 
 
3.3.9. Cell isolation and culture 
Human peripheral blood was collected from healthy volunteers who gave written 
consent and with specific approval from the Texas A&M University human subjects 
review board. All the methods were performed in accordance with the relevant 
guidelines and regulations. Peripheral blood mononuclear cells (PBMC) were isolated 
and collected from blood using Ficoll-Paque density gradient centrifugation (GE 
Healthcare, Cincinnati, OH) following the manufacturer’s protocol. PBMCs were 




culture plates (VWR) with RS (RPMI-1640 (VWR) supplemented with 10 mM HEPES 
(VWR), 1X non-essential amino acids (VWR), 1 mM sodium pyruvate (VWR), 2 mM 
glutamine (VWR), 100 U/ml penicillin, 100 μg/ml streptomycin (VWR), and 1X ITS-3 
(Sigma-Aldrich, St. Louis, MO)). When the cells were plated, recombinant human 
NEU3 (TP316537, Origene), was added to a final concentration of 0 – 500 ng/ml. The 
NEU3 was diluted in RS and added to cells to make the total volume of 200 μl in a well.  
The cells were then incubated at 37 ˚C with 5% CO2. The culture media supernatants 
were collected after 48 hours and assayed using interleukin-1β (IL-1β), IL-4, IL-6, IL-
10, IL-12, IL-13, or IFN-γ ELISA kits (Biolegend) following the manufacturer’s 
protocols, reading absorbance with a SynergyMX plate reader (BioTek, Winooski, VT). 
 
3.3.10. Flow cytometry analysis of sialidase expression in human PBMCs 
Human PBMC were cultured as above with 8.3 x 105 cells/ well with 2 ml/ well 
in 6-well tissue culture plates (VWR) in the presence or absence of recombinant human 
IL-6 (Biolegend) and IL-1β. After 72 hours, the medium was carefully removed and the 
cells were washed with 1 ml of sterile phosphate buffered saline (PBS) at room 
temperature.  The cells were detached with 500 μl of Accutase cell detachment solution 
(VWR) per well for 6 minutes at 37 °C. 1 ml of RS was added per well. After pipetting 
the cell solutions 4 times, the cells were placed in sterile 1.7 ml microtube tubes 
(Genesee Scientific, San Diego, CA) and cells were collected by centrifugation at 500 x 
g for 10 minutes at 4 °C.  The pelleted cells were washed twice by resuspension with 1 




2%(w/v) paraformaldehyde (EMS, Hatfield, PA), in PBS for 10 minutes on ice for 
fixation. 1 ml of ice-cold PBS was added and cells were collected by centrifugation.  The 
cells were resuspended in 200 μl of ice-cold PBSB, for 10 minutes on ice for blocking. 1 
ml of ice-cold PBS was added and cells were collected by centrifugation.  The pellet was 
resuspended in 200 μl of ice-cold 0.1% (w/v) Triton X-100 (Alfa Aesar, Ward Hill, MA) 
in PBS and cell membranes were lysed for 10 minutes on ice.  1 ml of ice-cold PBS was 
added and cells were collected by centrifugation.  Cells were resuspended in 500 µl of 
PBSB, and 125 µl was then collected by centrifugation for a staining reaction. 
 
The pelleted cells for a staining reaction were resuspended in 100 μl of 1 μg/ml 
rabbit polyclonal anti-NEU1 (Origene), anti-NEU2, (Origene,) anti-NEU4 
(Acris/Origene), irrelevant rabbit polyclonal antibody (AB-105-C, R&D Systems, 
Minneapolis, MN), or no antibody in 2% (w/v) PBSB, or 1 μg/ml anti-NEU3 (Origene) 
in 2% (w/v) PBSA with 0.1% (v/v) NP-40 alternative (EMD Millipore, Billerica, MA).  
Cells were incubated with antibodies for 60 minutes on ice. 500 μl of ice-cold PBS was 
added and cells were collected by centrifugation.  Cells were washed twice by 
resuspension in 1 ml of ice-cold PBS followed by centrifugation.  The cells were then 
incubated with 100 μl of 1:1000 goat anti-rabbit Alexa Fluor 647 (Life Technologies, 
Carlsbad, CA), in PBSB for 30 minutes on ice.  The cells were then washed twice as 
described above.  The cells were then resuspended in 100 μl of PBSB, kept on ice, and 




using forward- and side-scatter to identify monocytes and lymphocytes as described 
previously [47]. 
 
3.3.11. Lung tissue lysate preparation 
Approximately 10 – 12 mg of mouse lung tissue frozen in OCT was cut off, 
thawed, washed twice in 0.5 ml PBS by centrifugation at 2,000 x g for 5 minutes in a 
preweighed Eppendorf tube and resuspension. After the last centrifugation, the 
supernatant was carefully removed, and the tissue was weighed and the tube with tissue 
was frozen in liquid nitrogen. 500 μl of Pierce RIPA buffer (Thermo Scientific, 
Rockford, IL) with 1x proteases and phosphatases inhibitor cocktail (Cell Signaling 
Technology, Danvers, MA) was added per 5 mg of tissue and tissue was crushed with a 
pestle. The mixture was then incubated on a rotator for 2 hours at 4 °C. After 
centrifugation at 18,000 × g for 20 minutes at 4 °C, the supernatant was collected as lung 
tissue lysate. Total protein was measured by OD 280/260 with a SynergyMX plate 
reader, (BioTek, Winooski, VT) using RIPA buffer with protease and phosphatase 
inhibitor as a blank.  
 
3.3.12. NEU3 ELISA 
ELISA assays for NEU3 from BAL fluid were performed as described previously 
[160], with the exception that BAL fluid was diluted to 10 µg of protein in 100 μl of 
PBS. Serial dilutions of human recombinant NEU3 (Origene) in PBS were also 




3.3.13. Hydroxyproline assay 
Approximately half lobes of lungs frozen in OCT were cut off, thawed, and 
washed 3 times with PBS to remove OCT in preweighed Eppendorf tubes as described 
above. After the last centrifugation, the tubes were kept inverted for 5 minutes to allow 
PBS to blot onto blotting paper, and the tissue was then weighed.  Tissues were then 
processed using a hydroxyproline quantification kit (MAK008-1KT, Sigma Aldrich, St. 
Louis, MO), following the manufacturer’s directions. 
 
3.3.14. Statistical analysis 
Data were analyzed by t-test or ANOVA using Prism 7 (Graphpad, La Jolla, 
CA).  Significance was defined as p < 0.05. 
 
3.4. Results 
3.4.1. Neu3-/- mice do not lose weight after bleomycin treatment 
We previously observed that fibrotic lesions from human and mouse lungs have 
elevated levels of NEU3, and that in the bleomycin mouse model of pulmonary fibrosis, 
sialidase inhibitors attenuate fibrosis [160]. To determine if loss of NEU3 affects 
bleomycin-induced pulmonary inflammation and fibrosis, wild-type C57BL/6 and Neu3-
/- mice [178] were treated with an oropharyngeal aspiration of saline or bleomycin. The 
Neu3-/- mice had a disruption of the Neu3-/- gene (Figure 15 a – b), and undisrupted 
fragments of the Neu1, Neu2, and Neu4 genes (Figure 16 a – c). All of the mice survived 




C57BL/6 mice which developed a blocked intestine on day 10 after bleomycin aspiration 
and was sacrificed on day 10; this mouse was not included in the study. As previously 
observed [184, 185], compared to saline treated C57BL/6 mice (control), bleomycin 
treated C57BL/6 mice had lower body weights from days 6 to 12 after bleomycin 
(Figure 16 d). The weight gain of saline or bleomycin treated Neu3-/- mice was not 
significantly different from controls (Figure 16 c). Although there are differential effects 
of bleomycin in male and female mice [186, 187], similar trends were observed for male 
and female mice (Figure 16 e – f). Bleomycin treatment and/ or loss of NEU3 did not 
significantly affect liver, heart, kidneys or spleen weights (as a percent of total body 
weight) for combined male and female mice, (Figure 16 g), although Neu3-/- female mice 
had slightly increased liver weights after bleomycin (Figure 16 i). These data suggest 
that loss of NEU3 attenuates bleomycin-induced total body weight loss in mice. 
 
3.4.2. Neu3-/- mice have an attenuated protein increase in the BAL at day 21      
after bleomycin treatment 
Bleomycin treatment of mouse lungs causes protein levels in the BAL fluid to 
increase [111, 188, 189]. To determine if loss of NEU3 affects this, we measured protein 
in the BAL. As previously observed [111, 160], at day 21, bleomycin caused an 
upregulation of protein levels in BAL fluid in C57BL/6 mice as determined by scanning 
protein gels or by nanodrop assays (Figure 17 a, b, d, and f). Saline treated Neu3-/- mice 
had comparable levels of protein in BAL to those of C57BL/6 mice, and bleomycin did 





Figure 16. Sialidase genes, body weights, and organ weights.  
Tailsnip DNA was prepared from 3 randomly chosen wildtype C57BL/6 (+/+) and 3 
randomly chosen Neu3-/- (-/-) mice, and PCR was used to check for the presence of (a) a 
1041 basepairs (bp) fragment of the Neu1 gene, (b) a 572 bp fragment of the Neu2 gene, 
and (c) a 1482 bp fragment of the Neu4 gene. Molecular mass markers in basepairs are at 
left. neg indicates no-DNA control. (d) Percent change in body weight after saline or 
bleomycin treatment at day 0. Values are mean ± SEM, n = 6 except for bleomycin-
treated C57BL/6, where n=9. * indicates p < 0.05 comparing bleomycin treated Neu3-/- 
mice to bleomycin treated C57BL/6 mice (2way ANOVA, Bonferroni's test). Percent 
change in body weight after saline or bleomycin treatment at day 0 for (e) male mice and 
(f) female mice. Values are mean ± SEM, n = 3 except for bleomycin-treated C57BL/6 
mice, where n=5 for males and 4 for females. (g) Organ weights as percent of total body 
weight at day 21 of male and female mice together. Percent change in organ weights 
after saline or bleomycin treatment at day 0 for (h) male mice and (i) female mice. 
Values are mean ± SEM, n = 6 except for bleomycin-treated C57BL/6 mice, where n=9. 
The presence or absence of NEU3, and treatment with or without bleomycin, had no 








Figure 17. Neu3-/- mice do not have elevated BAL protein following bleomycin 
aspiration.  
BAL was collected at day 21 following saline or bleomycin treatment. (a) BAL from 3 
randomly selected mice per group were analyzed by PAGE on a 4-12 % reducing gel, 
and stained with Coomassie. Molecular mass markers in kDa are at left. Bovine serum 
albumin (BSA) at 0.01, 0.1, 1.0, and 10.0 μg was loaded at right. From left, lane # 1 - 12, 
the sex of mice is M, F, F, M, M, F, M, F, M, M, M, F, with M - Male and F - Female. 
(b) Quantification of protein in lanes # 1 – 12, using the BSA band densities as 
standards. Values are mean ± SEM, n=3. * p < 0.05, (1way ANOVA, Bonferroni's test). 
(c) BAL from the same mice were analyzed by PAGE on a reducing gel, and stained 
with anti- albumin antibodies. Molecular mass markers in kD are at left. Human albumin 
at 0.1 and 1.0 μg are in lanes 13 and 14. (d) BAL protein was measured using nanodrop 
(spectrophotometry). Values are mean ± SEM, n = 6 except for bleomycin-treated 
C57BL/6, where n=9. * p < 0.05 (t-test). (e) BAL volumes. Values are mean ± SEM, n = 
6 except for bleomycin-treated C57BL/6, where n=9. (f) Total BAL protein. BAL 
protein concentration was assessed by nanodrop spectrophotometry for each mouse, and 
multiplied by the BAL volume from that mouse to obtain total BAL protein. Values are 
mean ± SEM, n = 6 except for bleomycin-treated C57BL/6, where n=9. * p < 0.05, ** p 
< 0.01 (1way ANOVA, Bonferroni's test). 
 
previously observed [188], the bleomycin-induced protein in BAL appeared to be 




(Figure 17 c). Similar results were observed for female and male mice (Figure 18), 
although as previously observed [186], C57BL/6 female mice had an attenuated 
response to bleomycin, compared to C57BL/6 male mice. Although bleomycin seemed 
to increase BAL protein levels in female Neu3-/- mice, the effect was not statistically 
significant. Together these data suggest that loss of NEU3 attenuates bleomycin-induced 
upregulation of protein in BAL. 
 
 
Figure 18. BAL protein for male and female mice.  
The data from Figure 17 d, e, and f were separated for female (a – c) and male (d – f) 
mice. All values are mean ± SEM, n = 3 except for bleomycin-treated C57BL/6 mice, 






3.4.3. Neu3-/- mice have an attenuated inflammatory cell increase at day 21         
after bleomycin treatment 
Bleomycin upregulates inflammatory cell counts in mouse lung BAL [47, 107, 
111, 130]. Compared to saline treated C57BL/6 mice, saline treated Neu3-/- mice had 
similar BAL cell numbers (Figure 19 a). Compared to saline treated Neu3-/- mice, 
bleomycin treated Neu3-/- mice had upregulated BAL cell counts, but these were 
significantly less compared to bleomycin treated C57BL/6 mice (Figure 19 a). Similar 
effects were seen with male and female mice (Figure 20 a and b). Wright-Giemsa 
staining indicated that bleomycin treatment increased the lymphocyte percentage in both 
C57BL/6 and Neu3-/- BALs (Figure 19 b), but did not significantly affect monocyte/ 
macrophage percentages, compared to saline treatment (Figure 19 c). In C57BL/6 BAL, 
as previously observed [47, 111, 130], bleomycin increased the numbers of CD3 positive 
lymphocytes (Figure 19 d), CD11b positive inflammatory macrophages (Figure 19 e), 
CD11c positive resident alveolar macrophages (Figure 19 f), CD45 positive leukocytes 
(Figure 19 g), and Ly6G positive  cells in the BAL (Figure 19 i). Significant differences 
were not observed for CD19 positive lymphocytes (Figure 19 h) and Ly6C positive cells 
in the BAL (Figure 19 j).  Compared to saline treated C57BL/6 mice, saline treated 
Neu3-/- mice had similar BAL cell numbers for the above cell types, and in Neu3-/- mice, 
bleomycin upregulated CD11c positive cells in the BAL (Figure 19 f). Similar effects 
were seen in male and female mice with the exception that bleomycin caused an increase 
in CD45 positive cells in the BAL in Neu3-/- female, but not Neu3-/- male mice (Figure 





Figure 19. Neu3-/- mice have fewer BAL cells after bleomycin treatment. 
(a) The total number of cells collected from the BAL at day 21. Values are mean ± SEM, 
n = 6 mice per group except for bleomycin-treated C57BL/6, where n=9 mice per group. 
**** p < 0.0001 (1way ANOVA, Bonferroni's test), # p < 0.05 (t-test). Cytospins of 
BAL at day 21 were stained with Wright-Giemsa stain, the percent of (b) lymphocytes 
and (c) monocytes / macrophages was determined by examining 200 cells per mouse 
BAL sample. Values are mean ± SEM, n = 6 except for bleomycin-treated C57BL/6, 
where n=9. # p < 0.05 (t-test). Cytospins of BAL at day 21 were stained for the markers 
(d) CD3, (e) CD11b (f) CD11c, (g) CD45, (h) CD19, (i) Ly6G, (j) Ly6C, and (k) NEU1 
and NEU3.  The percent of cells stained was determined in 5 randomly chosen fields of 
100-150 cells, and the percentage was multiplied by the total number of BAL cells for 
that mouse to obtain the total number of BAL cells staining for the marker. Values are 
mean ± SEM, n = 6 except for bleomycin-treated C57BL/6, where n=9. * p < 0.05, *** p 







Figure 20. BAL cells for male and female mice.  
The data from Figure 19 a and d – j were separated for male (a and c) and female (b and 
d) mice. All values are mean ± SEM, n = 3 except for bleomycin-treated C57BL/6 mice, 
where n=5 for males and 4 for females. * p < 0.05 ** p < 0.01, *** p < 0.001 (1way 
ANOVA, Bonferroni's test), # p < 0.05 (t-test). (e) Percentage of positively stained cells 






expressing cells in BAL, compared to saline treated C57BL/6 mice (Figure 19 k). We 
did not observe any significant difference due to loss of NEU3 or presence of bleomycin 
in the percent of the above cell types in the BAL (Figure 20 e). Together, these data 
suggest that loss of NEU3 attenuates the bleomycin-induced increase of inflammatory 
cell counts in the BAL of Neu3-/- mice. 
 
Following BAL, lungs were sectioned and stained to detect cells that were not 
removed by BAL. As previously observed [47, 111, 130], in C57BL/6 mice bleomycin 
increased the numbers of Cd11b+, CD11c+, and CD45+ cells remaining in the lungs 
after BAL (Figure 21 a and b, Figure 22 a – c). Compared to saline treated C57BL/6 
mice, saline treated Neu3-/- mice had similar numbers for the above cell types, and in 
Neu3-/- mice, bleomycin did not significantly affect counts for the above cell types 
(Figure 21 a and b). As previously observed [190, 191], bleomycin did not affect counts 
of Ly6G+ or Ly6C+ cells in C57BL/6 lungs after BAL at day 21, and loss of NEU3 did 
not affect Ly6G+ or Ly6C+ counts (Figure 21 b, Figure 22 a – c). Female mice tended to 
have lower densities of the above cell types in the lungs (Figure 22 a and b). The 
positively stained cells were primarily clustered in the fibrotic regions of bleomycin-
treated C57BL/6 lungs (Figure 22 d). Together, these data indicate that Neu3-/- mice 





Figure 21. Immune cells remaining in the lungs after BAL. 
(a) Cryosections of day 21 lungs were stained with antibodies against CD45. Red is 
positive staining; blue is counter stain. Bar is 100 μm. (b) Cryosections of mouse lungs 
were stained for the indicated markers, and cells in 5 randomly chosen fields of view of 
45 µm diameter were counted, and the number was then calculated to number per mm2. 
Vales are mean ± SEM, n ≥ 6. * p < 0.05, ** p < 0.01, and *** p < 0.001 (1-way 
ANOVA, Bonferroni's test). 
 
 
3.4.4. NEU3 upregulates the pro-fibrotic cytokines IL-6 and IL-1β and IL-6 
upregulates NEU3 expression in human PBMCs 
We previously observed significant upregulation of extracellular and intracellular 
active TGF-β1 from human peripheral blood mononuclear cells (PBMCs) when cultured 
with human recombinant NEU3 [160]. To further investigate the role of NEU3 in 
upregulation of fibrotic cytokines, we cultured human PBMC with recombinant human 
NEU3 for 48 hours and then assayed the media supernatant by ELISA for the cytokines 
IL-1β, IL-4, IL-6, IL-10, IL-12, IL-13, and IFN-γ. We observed significant upregulation 
of extracellular accumulation of IL-6 and IL-1β with increasing concentrations of 
recombinant human NEU3 (Figure 23 a and b). We did not observe any significant effect 
of NEU3 on extracellular accumulation of IL-10, IL-13, and IFN-γ (Figure 24 a – c). 














Figure 22. Immune cells remaining in the lungs after BAL for male and female    
mice. 
The data from Fig. 21 b were separated for male (a) and female (b) mice. All values are 
mean ± SEM, n = 3 except for bleomycin-treated C57BL/6 mice, where n=5 for males 
and 4 for females. * p < 0.05, ** p < 0.01 (1-way ANOVA, Bonferroni's test), # p < 0.05, 
## p < 0.01 (t-test). (c) Serial cryosections of mouse lungs post BAL at day 21 were 
stained for the indicated markers (top) for the indicated groups (left). Red is staining, 
blue is counter stain. Bar is 200 μm. Images are representative of n = 6 mice per group 
except for bleomycin-treated C57BL/6 mice, where n=9. (d) Representative mosaic 
images of mouse lung cryosections stained with antibodies against CD45. Two individual 
images from the mosaic (black and yellow boxes) are shown at center and right. Red is 
staining, blue is counter stain. Bars are 200 μm. Images are representative of n = 6 mice 





Figure 23. NEU3 upregulates IL-6 and IL-1β, IL-6 upregulates NEU3, and Neu3-/- 
mice have less BAL IL-6 after bleomycin treatment. 
Human PBMC were cultured with recombinant human NEU3 and culture supernatants 
were assayed by ELISA for (a) IL-6 and (b) IL-1β. Values are mean ± SEM, n = 3. (c) 
Human monocytes and (d) human lymphocytes were cultured in human recombinant IL-
6 and cells were assayed for NEU 1 – 4 expression by flow cytometry. Values are mean 
± SEM, n = 3. * p < 0.05, ** p < 0.01, and *** p < 0.001 (2-way ANOVA, Bonferroni's 
test). (e) Human monocytes and (f) human lymphocytes were cultured in human 
recombinant IL-1β and cells were assayed for NEU 1 – 4 expression by flow cytometry. 
Values are mean ± SEM, n = 3. (g) BAL and (h) serum from the indicated mouse groups 
were collected at day 21 and assayed by ELISA for IL-6. Values are mean ± SEM, n = 6 
except for bleomycin-treated C57BL/6, where n=9. # p < 0.05 (t-test). (i)  BAL (j) serum 
from the indicated mouse groups were collected at day 21 and assayed by ELISA for IL-
1β. Values are mean ± SEM, n = 6 except for bleomycin-treated C57BL/6, where n=9. 
For (G) and (I), IL-6 and IL-1β were measured as μg per mg of total BAL protein, and 
values were normalized to the C57BL/6 saline mean values (4.6 ± 0.8 µg IL-6 / mg BAL 
protein and 1.8 ± 0.3 µg IL-1β/ mg BAL protein). For H and J, values were measured as 
pg/ ml of serum, and similarly normalized to the C57BL/6 saline mean values (8.1 ± 2.5 






Figure 24. Cytokine levels from human PBMCs. 
Human PBMCs were cultured with or without recombinant human NEU3 for 48 hours 
and culture supernatants were assayed by ELISA for (a) IL-10, (b) IL-13, and (c) IFN-γ. 
Values are mean ± SEM, n = 4 different donors for IL-10 and 5 different donors for IL-
13 and IFN-γ. No significant differences were observed (t-test). 
 
IL-6 upregulates NEU3 expression in carcinomas [192, 193]. To determine the 
effects of IL-6 and IL-1β on NEU3 expression by human PBMC, PBMC were cultured 
in the presence or absence of recombinant human IL-6 and IL-1β. 100 and 1000 pg/ml of 
IL-6 significantly increased NEU3 expression in monocytes (Figure 23 c) and 
lymphocytes (Figure 23 d). IL-1β did not significantly affect expression of NEU 1 – 4 in 
monocytes (Figure 23 e) or lymphocytes (Figure 23 f).  Together, these results suggest 
that NEU3 can upregulate pro-fibrotic cytokines such as TGF-β1 [160], IL-6, and IL-1β. 
Conversely, the ability of TGF-β1 [160], and IL-6 to upregulate NEU3 suggests that 
under some conditions, a positive feedback loop involving NEU3 and pro-fibrotic 







3.4.5. Neu3-/- mice have an attenuated IL-6 increase in the BAL at day 21 after 
bleomycin treatment 
To further investigate the role of NEU3 in bleomycin-induced pulmonary 
fibrosis, we tested if Neu3-/- mice have altered levels of fibrosis-associated cytokines in 
the BAL and serum. In C57BL/6 mice, bleomycin increased levels of the cytokine IL-6 
in the BAL but not the serum (Figure 23 g and h). Saline treated C57BL/6 and Neu3-/- 
mice had comparable levels of IL-6 in the BAL and serum, but bleomycin did not 
increase IL-6 in Neu3-/- BAL (Figure 23 g and h). No significant changes were observed 
in the levels of BAL and serum IL-1β in saline and bleomycin treated C57BL/6 and 
Neu3-/- mice (Figure 23 i – j). As observed previously [194-196], for C57BL/6 at day 21, 
bleomycin did not significantly affect levels of IL-1α, IL-10, IL-12p70, IL-17A, IL-23, 
IL-27, MCP-1, TNF-α, GM-CSF, IFN-β, and IFN-γ in BAL or serum (Figure 25 a and 
b). With or without bleomycin, the loss of NEU3 did not affect the levels of these 
cytokines in BAL or serum (Figure 25 a and b). These data suggest that NEU3 is 






Figure 25. Cytokine levels from mouse BAL and serum. 
(a) BAL and (b) sera were collected at day 21 and assayed by ELISA for the indicated 
cytokines. Values are mean ± SEM, n = 6 except for bleomycin-treated C57BL/6 mice, 
where n=9. Comparing the values in each group of four (C57BL/6 saline, C57BL/6 bleo, 
Neu3-/- saline, and Neu3-/- bleo), there were no significant differences (1-way ANOVA, 
Bonferroni's test). 
 
3.4.6. Neu3-/- mice show an attenuated upregulation of other sialidases at              
day 21 after bleomycin treatment 
As observed previously [160], compared to the BAL from saline treated 
C57BL/6 mice, upregulated levels of NEU3 were detected in the BAL from bleomycin 
treated C57BL/6 mice (Figure 26 a – c). No NEU3 was detected in saline or bleomycin 
treated Neu3-/- mouse BAL, when analyzed by western blot staining or ELISA for NEU3 
(Figure 26 a – c). Mice and humans have 3 other sialidases (NEU1, 2, and 4) in addition 




[52]. We previously observed that anti NEU1, NEU2, NEU3, and NEU4 antibodies are 
specific for the different sialidases [160]. As observed previously [160], the sialidases 
NEU1, NEU2, and NEU4 were not detected in the BAL from saline or bleomycin 
treated C57BL/6 mice, and these sialidases were also not detected in the BAL from 
saline or bleomycin treated Neu3-/- mice, even though some protein was present in these 
samples as determined by Ponceau-stained blots [180].  
 
Following BAL, lungs were sectioned and stained. As previously observed for 
C57BL/6 mice [37, 101, 103, 160], bleomycin increased staining for NEU1, NEU2, 
NEU3, and TGF-β1 in the lungs (Figure 26 d and e). As we observed for fibrotic human 
lungs, we also observed that bleomycin increased staining for NEU4 in the C57BL/6 
lungs (Figure 26 d and e); this was due to bleomycin increasing staining for NEU4 in 
female but not male lungs [180]. Further, as previously observed for C57BL/6 mice 
[197], females have smaller alveoli than males, and this appears to also be the case for 
Neu3-/- mice. (Figure 26 d).  
 
Compared to saline treated C57BL/6 mice, saline treated Neu3-/- mice had similar 
amounts of staining for NEU1, NEU2, NEU3, NEU4 and TGF-β1 in the lungs, and in 
Neu3-/- mice, bleomycin did not significantly affect staining for the above markers (Figure 





Figure 26. Neu3-/- mice have less sialidases and TGF-β1 in the lungs after    
bleomycin treatment.  
(a) BAL was collected at day 21 and BAL from 3 randomly chosen mice per group was 
analyzed by staining a western blot with anti-NEU3 antibodies. From left, in lane # 1 – 
12, the sex of mice is M, F, F, M, M, F, M, F, M, M, M, F, with M - Male and F - female. 
50 ng recombinant human NEU3 was loaded in lane # 13. Molecular mass markers in kDa  
are at left. (b) Densitometry of ~51 kDa NEU3 band, arbitrary units. *** p < 0.001 (1way 
ANOVA, Bonferroni's test). (c) BAL from the indicated groups were assayed by direct 
ELISA for NEU3 protein. Values are mean ± SEM, n = 6 except for bleomycin-treated 
C57BL/6, where n=9.  
 
 
regions of bleomycin-treated C57BL/6 lungs (Figure 27 a). The lung sections from 
bleomycin treated C57BL/6 mice were co-stained with antibodies against different 
cellular markers and antibodies against NEU3. In agreement with previous reports [149, 
160], where NEU3 is primarily expressed by epithelial cells, we observed NEU3 
expressed in CD11b positive monocyte derived macrophages, CD11c positive alveolar 
macrophages, CD31 positive cells, EpCAM positive epithelial cells, and SMA positive 
fibroblasts, with a high percentage of EpCAM positive epithelial cells expressing NEU3 






Figure 26. Continued. 
(d) Cryosections of male and female mouse lungs at day 21 were stained with antibodies 
against NEU1, NEU2, NEU3, NEU4, and active TGF-β1. Bar is 200 µm. Images are 
representative of 6 mice per group. (e) For each mouse, for each stain, three randomly 
chosen fields of view of the size shown in D were imaged, and the percent area of the field 
of view showing staining was measured, and the average was calculated. Values are mean 
± SEM, n = 6 averages. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (1-way ANOVA, 
Bonferroni's test). (f) Cryosections of bleomycin treated C57BL/6 mice were co-stained 
with antibodies against the indicated cell markers and NEU3. The percentage of cells 
stained for the indicated marker that also stained for NEU3 was calculated. Values are 






Western blots of lung tissue lysates were stained for NEU1, NEU2, NEU3, 
NEU4, and TGF-β1 (Figure 28 a – e). The relative protein levels were normalized to 
total protein from Coomassie gels (Figure 28 f). Compared to saline treated C57BL/6 
lysates, bleomycin treated C57BL/6 lysates had upregulated levels of NEU1 (Figure 28 a 
and g), NEU2 (Figure 28 b and h), NEU3 (Figure 28 c and i), NEU4 (Figure 28 d and j), 
and  
 
Figure 27. Representative images for NEU3 staining and cellular localization of 
NEU3 in fibrotic lesion. 
(a) Representative mosaic images of lung cryosections stained with anti-NEU3 
antibodies. Two fields of views (black and yellow box) are shown at center and right. 
Red is staining, blue is counter stain. Bars are 200 μm. Images are representative of n = 
6 mice per group except for bleomycin-treated C57BL/6 mice, where n=9. (b) Serial 
cryosections of bleomycin treated C57BL/6 mouse lungs post BAL at day 21 were 
stained with anti-NEU3 antibodies (green), the indicated cell markers (red), and DAPI 
(blue). Bar is 50 μm. Images are representative of 3 randomly selected bleomycin treated 
C57BL/6 mouse lungs. 
 
active TGF-β1 (Figure 28 e and k). Compared to saline treated C57BL/6 mice, saline 




NEU3, and NEU4 in lung lysates (Figure 28 a – k). Bleomycin did not upregulate 
NEU2, NEU3, or active TGF-β1 but did upregulate NEU1 and NEU4 in Neu3-/- lysates, 
albeit to a lesser level than in C57BL/6 lysates (Figure 28 a – k). Together, these results 
suggest that NEU3 protein is not detected in Neu3-/- mouse lungs, and that loss of NEU3 
reduces bleomycin induced increases in the levels of NEU1, NEU2, NEU4, and active 
TGF-β1 in the lungs. 
 
Figure 28. Sialidases and TGF-β1 in lungs lysates at day 21. 
Lysates of lung tissue from 3 randomly chosen mice per group were analyzed by western 
blots stained with (a) anti-NEU1 antibodies, (b) anti-NEU2 antibodies, (c) anti-NEU3 
antibodies, (d) anti-NEU4 antibodies, and (e) anti-TGF-β1 antibodies. (e”) A long 
exposure of ‘e’ was used to detect active TGF-β1 at ~ 25 kDa. (f) A gel of the samples 
was stained with Coomassie blue to detect total protein. Molecular mass markers in kDa 
are at left. 100 – 140 ng of human recombinant NEU1, NEU2, NEU3, NEU4, and active 
TGF-β1 was added in lane #13-14 of gels (a), (b), (c), (d), and (e – e”). Quantification of 
relative intensity normalized with total protein for (g) NEU1, (h) NEU2, (i) NEU3, (j) 
NEU4, and (k) active TGF-β1 from the e” image. Values are mean ± SEM, n = 3. * p < 





3.4.7. Neu3-/- mice have decreased fibrosis at day 21 after bleomycin treatment 
To determine if loss of NEU3 affects the fibrotic response to bleomycin, lung 
sections were stained with hematoxylin and eosin to detect tissue, antibodies to detect 
collagen-I, picrosirius red to detect total collagen (which was also imaged using 
polarized light microscopy for qualitative analysis), and hydroxyproline levels were  
 
Figure 29. Neu3-/- mice have less fibrosis in the lungs after bleomycin treatment. 
Day 21 lung cryosections were stained with (a) H&E, (b) picrosirius red to show 
collagen content, and (c) antibodies against collagen-I. Bars are 200 µm. For A and B, 
images are representative of n = 6 mice per group except for bleomycin-treated 
C57BL/6, where n=9. For C, images are representative of 4 randomly chosen (2 male 
and 2 female) mice per group. For (d) picrosirius red quantification and (e) collagen-I 
quantification, 5 randomly chosen fields of view of the sizes shown in B and C were 
imaged for each mouse, and the average percent area of the field of view showing 
staining for each mouse was measured. (f) Estimation of hydroxyproline from saline or 
bleomycin treated C57BL/6 wildtype and Neu3-/- mice lungs. (g) Percent of alveolar wall 
area fraction was determined by the ratio of area of alveolar walls to the total image area. 
For d, f, and g, values are mean ± SEM, n = 6 except for bleomycin-treated C57BL/6, 
where n=9, and for E values are mean ± SEM, n = 4. * p < 0.05, ** p < 0.01, *** p < 
0.001 (1-way ANOVA, Bonferroni's test), # p < 0.05 (t-test). 
 
measured in tissue hydrolysates. As previously observed for C57BL/6 mice [182, 198-
200], bleomycin caused fibrosis in the mouse lungs (Figure 29 a – f). Bleomycin did not 




increased collagen-I staining and increased alveolar wall area fraction in Neu3-/- mouse 
lungs, but the increase was less than in bleomycin treated C57BL/6 mice (Figure 29 d – 
f; Figure 30 a). Similar results were observed for male and female mice (Figure 30 b – g) 
with the exception that bleomycin treated Neu3-/- female mice had significantly 
upregulated sirius red staining compared to saline treated Neu3-/- female mice, whereas 
this was not observed for male mice (Figure 30 b and c). Conversely, bleomycin treated 
Neu3-/- male mice had significantly upregulated alveolar wall area fraction, compared to 
saline treated Neu3-/- male mice, whereas this effect did not reach significance for female 
mice (Figure 30 f and g). Polarized light microscopy of lung sections stained with sirius 
red showed qualitative upregulation of collagen in bleomycin treated C57BL/6 mice, 
compared to saline treated C57BL/6 mice or saline and bleomycin treated Neu3-/- mice 
(Figure 30 h). These results suggest that loss of NEU3 significantly decreases the 






Figure 30. Fibrosis in male and female mice. 
(a) Hydroxyproline standard curve. The data from Fig. 29 d, f and g were separated for 
male (b, d and f) and female (c, e and g) mice. All values are mean ± SEM, n = 3 except 
for bleomycin-treated C57BL/6 mice, where n=5 for males and 4 for females. * p < 0.05, 
** p < 0.01 (1way ANOVA, Bonferroni's test), # p < 0.05, ## p < 0.01 (t-test). (h) 
Representative mosaic images of cryosections stained with Sirius red and imaged with 
polarized light. Two individual images from the mosaic (black and yellow boxes) are 
shown at center and right. Bars are 200 μm. Images are representative of n = 6 mice per 






In this report, we observed that loss of the sialidase NEU3 in male and female 
mice attenuated bleomycin-induced weight loss, upregulation of protein levels in the 
BAL, inflammation, TGF-β1 upregulation, and fibrosis, and that the loss of NEU3 did 
not appear to be compensated by the upregulation of other sialidases. These results 
suggest that NEU3 may have a major role in bleomycin-induced pulmonary fibrosis in 
mice. 
 
 We observed attenuated total inflammatory cell counts, but no significant 
differences in the percentages of the different cell types, in the BAL of bleomycin 
treated Neu3-/- compared to bleomycin treated C57BL/6 mice, suggest that attenuation of 
bleomycin-induced pulmonary fibrosis in the Neu3-/- mice is not dependent on the ratios 
of the different cell types in the BAL.  
 
Changes in cytokine levels are associated with, and appear to drive, fibrosis [83]. 
We observed that NEU3 upregulates extracellular accumulation of IL-6 by human 
PBMCs, which is in agreement with previous reports where addition of NEU3 to cells 
upregulates IL-6 [192, 193]. IL-6 potentiates fibrosis [170], and is actively involved in 
epithelial-to-mesenchymal transition (EMT) which is associated with fibrosis [201, 202]. 
We observed bleomycin-induced upregulation of IL-6 in the BAL fluid of C57BL/6 
mice but not Neu3-/- mice, suggesting that NEU3 may be an important driver of the 




in human PBMCs by IL-6, which is in agreement with a previous report where IL-6 
increases NEU3 expression in renal cell carcinoma cells [56]. Together, these results 
suggest that NEU3 mediated upregulation of IL-6, and IL-6 mediated upregulation of 
NEU3, might form a NEU3 – IL-6 – NEU3 positive feedback loop that potentiates 
fibrosis. 
 
IL-1β is also associated with inflammatory and fibrotic responses [203]. In the 
presence of serum, IL-1β upregulates NEU1 but not NEU3 in human neutrophils [34] 
and in monocytes/macrophages in a positive feedback loop [54]. In the absence of 
serum, we observed that NEU3 upregulates IL-1β, but IL-1β does not upregulate NEU3 
in human PBMC. Together, these results suggest that as with IL6, NEU3 may form a 
positive feedback loop with IL-1β and that something is serum is necessary for IL-1β 
upregulation of NEU3.  
 
We previously reported upregulation of NEU1, NEU2, and NEU3, but not 
NEU4, in fibrotic lesions of lung tissue from male mice at day 21 after bleomycin 
aspiration [160]. A recent report found that NEU1 is down regulated in IPF, that Neu1-/- 
fibroblasts have characteristics of myofibroblasts, and that Neu1-/- fibroblasts release the 
pro-fibrotic cytokine TGF-β1, suggesting that NEU1 does not potentiate fibrosis [204]. 
Here we observed upregulation of NEU4 in lung tissue from C57BL/6 female mice but 
not male mice at day 21 after bleomycin. Bleomycin has different effects on male versus 




linked differential effect of bleomycin in mice. The lack of NEU4 upregulation in 
fibrosis in male mice suggests that NEU4 upregulation is not a key driver of fibrosis. 
The observation that mice lacking NEU3 do not upregulate NEU2, and the above 
observations about NEU1 and NEU4, suggest that NEU2 and/or NEU3 may be 
responsible for the extensive desialylation that occurs in the lungs in response to 
bleomycin [160].  
 
The Ensembl database ENSG00000162139 for human [205] shows that for 
NEU3 there are 7 different protein coding splice variants. Similarly, for mouse, the 
NCBI gene ID: 50877 shows at least three NEU3 protein coding transcripts. In 
agreement with the concept of different NEU3 splice variant transcripts, at least 5 
variants of NEU3 transcripts have been observed in zebrafish [206]. Transcriptomic data 
shows that there are at least 9 different splice variants for NEU3 from human IPF patient 
lungs [161]. There are multiple NEU3 proteins in human cell lines [207]. Other workers 
also found multiple NEU3 variant proteins in human cells [37, 149, 208], and looking at 
10 different human cell lines, we also observed multiple variants, with different variants 
expressed by different cell types [160]. In the same publication, we observed that TGF- 
β1 causes upregulation of NEU3 in PBMC, airway epithelial cells, A549 cells, and lung 
fibroblasts. We observed NEU3 expressed in multiple cell types in fibrotic mouse lungs. 
Together, this suggests the possibility that in bleomycin-induced fibrosis, multiple cell 
types express multiple NEU3 variants, leading to the multiple NEU3 bands we observed 




of these bands were upregulated by bleomycin treatment. None of these bands were 
observed in the BAL or lung tissue from saline- or bleomycin-treated NEU3 knockout 
mice, indicating that the multiple NEU3 bands observed in the WT mice are bona fide 
NEU3 proteins.  
 
There are upregulated levels of the mRNA encoding NEU1 in the lung 
fibroblasts from some pulmonary fibrosis patients [37]. Single-cell transcriptomic 
analysis also showed upregulated levels of NEU1 transcripts in lung cells from 
pulmonary fibrosis patients [209]. A different study however found no significant 
increases in the mRNAs encoding NEU1 – 4 in IPF patients compared to healthy 
individuals [161]. However, we consistently found elevated levels of NEU3 protein in 
the fibrotic lesions in human and mouse lungs [160]. We also found that the profibrotic 
cytokine TGF- β1 [101, 103] causes a variety of cell types to upregulate NEU3 [160]. 
Since TGF-β1 regulates the levels of some proteins by a post-transcriptional mechanism 
[162], we previously hypothesized that the increased levels of NEU3 observed in 
pulmonary fibrosis may be due to a post-transcriptional mechanism [160]. The 
observation that the antibody we used for the previous work does not detect proteins in 
mice lacking NEU3 reinforces the validity of this assay, and in combination with the 
NEU3 transcriptomic analysis suggests that in fibrosis there may be post-transcriptional 





Active TGF-β1 is a key driver of fibrosis [101, 103]. We previously discussed a 
possible positive feedback loop involving NEU3 – TGF-β1 – NEU3 in the progression 
of pulmonary fibrosis [160]. In this report we observed upregulated levels of active 
TGF-β1 in lung tissues of bleomycin treated C57BL/6 mice, but not in the lung tissues 
of bleomycin treated Neu3-/- mice. TGF-β1 is sequestered in an inactive state by latency-
associated peptide (LAP) in a complex called latent TGF-β1 protein (LTGF-β1) [89]. 
LTGF-β1 has three glycosylated asparagine residues at position 82, 136, and 176, all in 
the LAP sequence [89, 91]. Bacterial and viral sialidases can desialylate LAP, causing a 
conformational change that releases active TGF-β1, and this is thought to explain the 
elevated TGF-β1 levels observed during some infections [92, 93, 96, 210, 211]. In 
bleomycin treated Neu3-/- mice, we did not observe upregulated levels of active TGF-β1 
(~25 kDa). On Western blots of saline or bleomycin treated Neu3-/- mouse lung tissue 
electrophoresed on non-reducing/ no SDS gels (which preserve the LAP/ TGF-β1 
complex [96, 212]), we observed anti- TGF-β1 antibodies staining a ~60kDa band, 
which is the previously reported size of the LAP/ TGF-β1 complex (Figure 28 e). These 
results suggest that NEU3 may be involved in releasing active TGF-β1 from LTGF-β1 in 
bleomycin induced pulmonary fibrosis.  
 
The loss of NEU3 attenuates bleomycin-induced increases in protein and 
albumin in BAL fluid, which may well be due to vascular leakage. IL-6 causes vascular 
leakage [213-215] . The loss of NEU3 also attenuates bleomycin-induced inflammation, 




inhibits bleomycin-induced IL6 upregulation in the BAL. Thus, one possible explanation 
for the reduced inflammation in, and reduced levels of protein and albumin in the BAL 
of, bleomycin treated Neu3-/- cells is that in a wild-type lung, the damage caused by 
bleomycin causes an upregulation of NEU3, the upregulated NEU3 upregulates IL-6, 
and the IL-6 induces inflammation and vascular leakage. In the absence of NEU3, the 
upregulation of IL-6, inflammation, and leakage then do not occur.  
 
We previously observed that TGF-β1 upregulates NEU3, and that NEU3 
upregulates TGF-β1, which suggested that a NEU3 - TGF-β1 – NEU3 positive feedback 
loop potentiates fibrosis. [160]. In this report we observed that IL-6 upregulates NEU3, 
and that NEU3 upregulates IL-6 and IL-1β. These results suggest that NEU3 participates 
in at least 2 positive feedback loops, one with TGF-β1 driving fibrosis, and the other 
with IL-6 driving vascular leakage, inflammation, and fibrosis. Thus, the extent to which 
NEU3 - dependent bleomycin-induced vascular leakage and inflammation contribute to 
NEU3 – dependent bleomycin-induced fibrosis is unclear.  
 
Given that we previously observed increased levels of NEU3 in the fibrotic 
lesions in the lungs of IPF patients, and that the sialidase inhibitors DANA and 
Oseltamivir attenuate bleomycin induced pulmonary fibrosis in mice, our results suggest 






4. INHIBITING SIALIDASE-INDUCED TGF-Β1 ACTIVATION ATTENUATES 
PULMONARY FIBROSIS IN MICE ‡ 
 
4.1. Summary 
Pulmonary fibrosis involves the formation of inappropriate scar tissue in the 
lungs, but what drives fibrosis is unclear. The active form of transforming growth factor-
β1 (TGF-β1) plays a key role in potentiating fibrosis. TGF-β1 is sequestered in an 
inactive state by a latency associated glycopeptide (LAP). Sialidases (also called 
neuraminidases) cleave terminal sialic acids from glycoconjugates. The sialidase NEU3 
is upregulated in fibrosis, and mice lacking Neu3 show attenuated bleomycin-induced 
increases in active TGF-β1 in the lungs, and attenuated pulmonary fibrosis. Here we 
observe that recombinant human NEU3 upregulates active human TGF-β1 by releasing 
active TGF-β1 from its latent inactive form by desialylating LAP. Based on the proposed 
mechanism of action of NEU3, we hypothesized that compounds with a ring structure 
resembling picolinic acid might be transition state analogues and thus possible NEU3 
inhibitors. Some compounds in this class showed nanomolar IC50s for recombinant 
human NEU3 releasing active TGF-β1 from recombinant human latent inactive form. 
The compounds given as daily 0.1 mg/kg – 1 mg/kg injections starting at day 10 strongly 
attenuated lung inflammation, lung TGF-β1 upregulation, and pulmonary fibrosis at day 
 
‡ Reprinted with permission from “Inhibiting Sialidase-induced TGF-β1 Activation Attenuates Pulmonary 
Fibrosis in Mice.” TR Karhadkar, TD Meek, and RH Gomer (2020). 
DOI: https://doi.org/10.1124/jpet.120.000258 American Society for Pharmacology and Experimental 




21 in the mouse bleomycin model. These results suggest that NEU3 participates in in 
fibrosis by desialylating LAP and releasing TGF-β1, and that the new class of NEU3 
inhibitors are potential therapeutics for fibrosis. 
 
4.2. Introduction 
Fibrosis involves scar-like tissue forming in an internal organ leading to organ 
failure [10]. Pulmonary fibrosis has an incidence of 1 in 400 in the elderly, and there are 
no FDA-approved therapeutics that stop the progression of this disease [2, 12, 13]. 
Transforming growth factor-β1 (TGF-β1) in its active mature form is a key factor which 
potentiates fibrosis [101, 103]. TGF-β1 is synthesized as a precursor protein made of 
latency-associated peptide (LAP) and the active TGF-β1 in a complex called latent-TGF-
β1 (LTGF-β1) [86, 89]. Two dimerized TGF-β1 precursor proteins are processed to 
cleave active TGF-β1 from the LAP, with the LAP remaining essentially wrapped 
around, and sequestering, the TGF-β1 [86]. There are also additional processes that takes 
place on the dimerized precursor protein as it passes through the endoplasmic reticulum 
(ER) to the Golgi complex which includes glycosylation and sialylation of the LAP 
sequence before the complex is secreted [86, 89-91, 219] . 
 
Several things can release active TGF-β1 from sequestration by the LAP. Both 
the integrin αvβ6, which generates mechanical traction on the LAP, and 
thrombospondin-1 can release active TGF-β1 [220, 221]. Proteases such as plasmin, 




changes in LAP, can also release TGF-β1 from the LAP [222-225] However, it is 
unclear if these are the only mechanisms that cause upregulation of active TGF-β1 in 
fibrotic lesions.  
 
Neuraminic acid (also known as sialic acid) is a nine-carbon monosaccharide 
sugar found at the terminal ends of some glycoproteins [39, 42, 44]. The presence or 
absence of sialic acid on terminal ends of the these glycoconjugates have a central role in 
various cellular regulatory mechanisms [45, 226]. For instance, adding sialic acids to the 
glycan residues on immunoglobulin G (IgG) confers anti-inflammatory functions to IgG 
[227]. Conversely, the loss of sialic acid from the plasma protein Serum amyloid P 
(SAP) attenuates the potency of SAP to inhibit the differentiation of some human 
peripheral blood mononuclear cells (PBMC) to fibrosis-associated fibroblast-like cells 
called fibrocytes [47]. 
 
Neuraminidases (also known as sialidases) are enzymes that catalyze a 
hydrolysis reaction which removes terminal sialic acids from glycoconjugates [18, 19, 
28]. There are four known mammalian sialidases [19, 28]. Of the four, the sialidase 
NEU3 is localized in endosomal structures and on the extracellular side of the plasma 
membrane, and under some conditions can also be released by cells, and thus can 
desialylate glycoproteins and glycolipids present outside the cell [29, 52, 207, 228, 229]. 
Sialidases, especially NEU3, are upregulated in pulmonary fibrosis [38, 160, 230]. TGF-




epithelial cells, and PBMC [160]. In the epithelial cells, TGF-β1 increases levels of 
NEU3 by decreasing the NEU3 degradation rate and increasing NEU3 mRNA 
translation [231]. Conversely, NEU3 upregulates TGF-β1 in human PBMCs and human 
pulmonary fibroblasts [160]. Intratracheal delivery of bleomycin upregulates TGF-β1 in 
the lungs [84, 232], and is a standard model of pulmonary fibrosis in mice [151, 198]. 
Mice lacking NEU3, or wild-type mice treated with sialidase inhibitors, do not 
upregulate TGF-β1 in the lungs after bleomycin treatment, and show attenuated 
bleomycin-induced pulmonary fibrosis [160, 180]. Together, these observations 
suggested that a positive feedback loop where TGF-β1 upregulates NEU3, and NEU3 
upregulates TGF-β1, may potentiate fibrosis [160, 180]. How NEU3 upregulates TGF-
β1 is unknown.  
 
In vitro, bacterial and viral sialidases can desialylate LTGF-β1, leading to the 
release of active mature TGF-β1, possibly explaining why there are elevated levels of 
active TGF-β1 levels during infection with sialidase-expressing pathogens [92, 93, 96, 
210, 212]. There have been many previous attempts to develop inhibitors for viral [233] 
or human [155] sialidases. Examples of viral sialidase inhibitors include Tamiflu 
(oseltamivir) and Relenza (zanamivir), which can attenuate the progression of influenza 
in a patient [234-237]. Potent inhibitors for viral neuraminidases exert poor inhibition for 
human neuraminidases [238, 239]. There are a variety of inhibitors for human sialidases, 
but all have published IC50s of ~10 µM for NEU3, making them relatively weak 




In this report, we find that NEU3 desialylates LAP to release active TGF-β1. We 
then identified a new class of potent NEU3 inhibitors, some with IC50s in the nM range. 
These compounds inhibit bleomycin induced pulmonary fibrosis in mice, further 
supporting the idea that NEU3 inhibitors may be potential therapeutics for fibrosis. 
 
4.3. Materials and methods 
4.3.1. Cell isolation and culture 
Human peripheral blood was collected from healthy volunteers who gave written 
consent and with specific approval from the Texas A&M University human subjects 
review board. All methods were performed in accordance with the relevant guidelines 
and regulations. Blood collection, isolation of PBMC, and cell culture were done as 
described previously [127, 128]. 
 
4.3.2. Mouse NEU3 expression in HEK 293-f cells 
HEK 293 freestyle cells (Life Technologies, Grand Island, NY) were cultured in 
FreeStyle 293 media (12338-018, Life Technologies). 1 x 105 cells were mixed with 2 
μg of 100 μg/ml of murine Neu3 expression clone (MR223297, Origene, Rockville, 
MD) in 100 μl PBS (GE Lifesciences, Marlborough, MA), and were transfected by 
electroporation using a 4D-Nucleofector System (Lonza, Walkersville, MD) following 
the manufacturer’s protocol. The transfected cells were kept at room temperature for 15 
minutes for recovery, after which the cells were cultured in 25 ml Freestyle 293 media in 




(345812, Calbiochem EMD, San Diego, CA) was added to select for transfected cells. 
After 10 days, the cells were isolated, lysed, and c-Myc tagged recombinant mouse 
NEU3 was purified using a Myc-Trap_A kit (ytak-20, Chromotek, Hauppauge, NY) 
following the manufacturer’s protocol. The eluted protein was stored in 50 μl of 10% 
glycerol, 100 mM glycine, 25 mM Tris-HCl pH 7.3, at 4 °C. 
 
4.3.3. Human NEU3 expression in E. coli 
The human NEU3 cDNA sequence was amplified from a human NEU3 ORF 
clone (RC216537, Origene). The amplified NEU3 sequence was inserted between the 
NdeI and EcoRI sites of the pMAL-c5X vector (N8108S, NEB, Ipswich, MA). The 
resulting construct encoding a fusion of maltose-binding protein (MBP) and NEU3 was 
transformed into chemically competent E. cloni cells (Lucigen, Middleton, WI) mixed in 
37 °C pre-warmed Luria-Bertani (LB) broth (#240230, BD, Franklin Lakes, NJ), grown 
with shaking at 37 °C, 240 rpm for 1 hour and plated on LB agar with ampicillin (100 
μg/ml). Clones were selected and grown in 100 μg/ml ampicillin LB broth medium, and 
the plasmids were isolated using a GeneJET Plasmid Miniprep Kit (#K0502, Thermo 
Scientific, Waltham, MA). Clones were verified by sequencing (Eton Bioscience, San 
Diego, CA). The sequence verified clones were transformed into chemically competent 
BL21(DE3) E. coli cells (Lucigen), grown with shaking at 37 °C, 240 rpm, for 1 hour in 
pre-warmed LB broth, and plated on LB agar with 100 μg/ml ampicillin. Individual 
colonies were selected and added to 10 ml pre-warmed LB broth with 100 μg/ml 




added to 1 L of LB broth and incubated at 37 °C, 240 rpm until OD600 ~0.6. To induce 
protein expression, isopropyl β- d-1-thiogalactopyranoside (IPTG, Goldbio, St. Louis, 
MO) solution was added to 0.5 mM, and incubated at 20 °C at 240 rpm overnight. 
Protein purification was done as described previously [241] with the following 
modifications. Bacterial cells were harvested after 16 – 18 hours of induction by 
centrifugation at 4000 × g at 4 °C. The pellet was resuspended in resuspension buffer (20 
mM Tris, pH 7.2, 300 mM NaCl, 1 mM EDTA and 0.1% Triton X-100) supplemented 
with 1x protease inhibitor (PIA32965, VWR, Radnor, PA). The lysate was sonicated 
three times for three minutes with the tube submerged in ice at setting 16 of a Microson 
ultrasonic cell disruptor (Misonix Incorporated, Farmingdale, NY), and then clarified by 
centrifugation at 10,000 × g for 20 minutes at 4 °C. The supernatant was loaded onto an 
amylose column (New England Biolabs) equilibrated with 20 mM Tris/ 300 mM NaCl, 
pH 7.2. MBP-NEU3 was eluted with running buffer containing 10% glycerol (v/v) and 
20 mM maltose. 
 
4.3.4. Sialidase effects on LAP assay 
To determine the effect of sialidases on latency associated peptide (LAP), 400 
ng/ml human recombinant latency-associated peptide (LAP), (246-LP/CF, R&D 
Systems, Minneapolis, MN) was incubated with and without 200 ng/ml of human 
recombinant sialidases NEU1 (TP300386, Origene), NEU2 (TP319858, Origene), NEU3 
(TP316537, Origene), or NEU4 (TP303948, Origene), or C. perfringens neuraminidase 




phosphate buffered saline (PBS; #SH30256.01, GE Lifesciences) pH 6.9. The PBS was 
adjusted to pH 6.9 with 12N HCl (H613-05, Avantor Performance Materials, Radnor 
Township, PA). The reaction mixtures were incubated at 37 °C for 2 hours. Following 
incubation, 5 μl of 4x Laemmli’s buffer (GTX16355, GeneTex, Irvine, CA) containing 
20 mM dithiothreitol was added to the reaction mixtures, and these were heated at 100 
°C for 5 minutes. 15 μl of the heated reaction mixture was electrophorized on a 4-20% 
Tris/glycine polyacrylamide pre-cast gel (12001-058, VWR, Radnor, PA) in 
Tris/glycine/SDS running buffer (13.5 g Tris base, 7.2 g glycine, 5 g SDS / liter) at room 
temperature for 90–120 minutes.  
 
Western blots, and staining the blots with lectin, was done as previously described [47], 
and immunostaining western blots for NEU3 was done as previously described [160, 
180]. Silver staining of gels was done following [244]. Staining intensity was quantified 
by Image Lab software (Bio Rad, Hercules, CA).  
 
4.3.5. NEU3 induced L-TGF-β1 activation assay 
To determine if NEU3 can cause latent transforming growth factor-β1 (L-TGF-
β1) to release active TGF-β1, 200 ng/ml recombinant human latent transforming growth 
factor-β1 (L-TGF-β1) (299-LT/CF, R&D Systems) was incubated with varying 
concentrations of recombinant human NEU3 (TP316537, Origene) or bacterially 
expressed recombinant human NEU3, in a total volume of 100 µl of PBS pH 6.9 in a 96-




°C for 2 hours. Following incubation, the reaction mixtures were assayed using an active 
TGF-β1 ELISA kit (DY240, R&D Systems) following the manufacturer’s protocol with 
the exception that the reaction mixtures were not processed for acid treatment, so as to 
measure only active TGF-β1 and not total TGF-β1. The absorbance was read with a 
SynergyMX plate reader (BioTek, Winooski, VT). To determine the enzyme kinetics of 
NEU3 with L-TGF-β1 as a substrate, varying concentrations of L-TGF-β1 were 
incubated with 100 ng/ml of recombinant human NEU3 (Origene), in a total volume of 
100 μl, and the samples were processed as described above. 
 
4.3.6. Sialidase activity assay with 2′-(4-methylumbelliferyl)-α-D-N-
acetylneuraminic acid sodium salt hydrate (4MU-NANA) 
Sialidase assays were done following [134, 135] with the following 
modifications. PBS was adjusted to pH 6.9 with 12N HCl and bovine serum albumin 
(BSA, VWR) was added to a final concentration of 100 μg/ml (PBS-BSA). Varying 
concentrations of bacteriailly expressed recombinant human NEU3 were prepared in 
PBS-BSA. A final concentration of 200 μM 4MU-NANA (M8639, Sigma-Aldrich) was 
added to the NEU3 in a total volume of 100 μl in a 96-well plate. Where indicated, 
inhibitors were added for 30 minutes before adding the 4MU-NANA. The reactions were 
incubated at 37 °C for 30 minutes, and the fluorescence was measured at 37 °C in a 
prewarmed SynergyMX plate reader with excitation at 360 nm and emission at 440 nm. 





4.3.7. Inhibition of NEU3 induced L-TGF-β1 activation  
2,3-didehydro-2-deoxy-N-acetyl-neuraminic acid (DANA) was purchased from 
EMD-Millipore (Burlington, MA), Oseltamivir phosphate (Tamiflu) was purchased from 
Sigma, 2-acetyl pyridine (sc-254121) and methyl picolinate (sc-228575) were from 
Santa Cruz Biotechnology (Dallas, TX), and 2-piperidinecarboxylic acid, 4-amino-1-
methyl (A00285-13785-026) was from Sundia (Shanghai, China). These compounds 
were dissolved in water to 20 mM. All stocks were stored at 4 °C and used within 2 
weeks of preparation. Dilution series of the compounds were made in PBS pH 6.9. 100 
µl of diluted compound was added to the well of a 96 well plate and then 50 µl of 400 
ng/ml recombinant human sialidase NEU3 (TP316537,Origene) in PBS pH 6.9 was 
added to each well (50 µl PBS pH 6.9 for the control), and the plate was incubated for 30 
minutes at 37 °C. 50 µl of 800 ng/ml L-TGF-β1 (299-LT/CF, R&D Systems) in PBS pH 
6.9 was then added to the well. The plate was covered with aluminum foil and incubated 
for 2 hours at 37 °C, and released active TGF-β1 was assayed as described above. 
 
4.3.8. Inhibition of NEU3 induced IL-6 accumulation  
Dilutions of the above compounds were made in serum-free medium prepared as 
previously described [127, 180], and 50 µl of diluted compound was added to the well of 
a 96 well plate and then 50 µl of 400 ng/ml recombinant human sialidase NEU3 
(TP316537, Origene) in serum-free medium was added to each well (50 µl serum-free 
medium for control), and the plate was incubated for 30 minutes at 37 °C in a humidified 
incubator with 5% CO2. 100 µl of PBMC at 1 x 10




to make the total volume in a well 200 μl with 1 x 104 cells/well, and this was incubated 
at 37 °C in a humidified incubator with 5% CO2 for 48 hours. IL-6 in the culture 
supernatant was then assayed with an IL-6 ELISA kit (430501, BioLegend, San Diego, 
CA) following the manufacturer’s protocol, reading absorbance with a SynergyMX plate 
reader (BioTek).  At least three different donors were used for each assay. 
 
4.3.9. Mouse model of pulmonary fibrosis 
To determine if the NEU3 inhibitors affect pulmonary fibrosis in mice, 8-10 
week old 26–30 g male C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) were 
given an oropharyngeal aspiration of 3 units/kg bleomycin (2246-10, BioVision 
Incorporated, Milpitas, CA) in 50 µl of 0.9% saline to induce symptoms of pulmonary 
fibrosis or oropharyngeal saline alone as a control as previously described [47, 111, 
130]. Starting 10 days after bleomycin had been administered, some of the bleomycin-
treated mice were given daily intraperitoneal injections of 100 μl of PBS or 1 mg/kg 2-
acetyl pyridine, 1 mg/kg methyl picolinate, or 0.1 mg/kg of 2-piperidinecarboxylic acid, 
4-amino-1-methyl in 100 µl PBS. All mice were weighed daily for 21 days after 
bleomycin was adminstered. At day 21, mice were euthanized by CO2 inhalation, and 
bronchoalveolar lavage (BAL) fluid and cell-spots of BAL cells were obtained as 
previously described [47, 111, 130, 131]. The liver, heart, kidneys, spleen, white fat 
tissue, and brown fat tissue were removed and weighed. The total cells from BAL cell-
spots were quantified as described previously [111, 131]. The lungs were removed and 




and preserved at -80 °C. 6–10 µm cryosections of lungs were placed on glass slides 
(48311-703, VWR) and were air dried for 48 hours before use. The mouse experiments 
were performed in accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of Health. The Texas A&M 
University Animal Use and Care Committee approved the protocol (IACUC 2017-0414). 
 
4.3.10. Histology, immunohistochemistry, and BAL analysis 
Air dried cryosections were stained with hematoxylin and eosin or with Sirus red 
to detect collagen, or with 1 μg/ml anti-active TGF-β1 antibodies (AB-100-NA, R&D 
Systems, Minneapolis, MN) as described previously [15, 160]. The staining was 
quantified with ImageJ [143, 144]. Immunohistochemistry on BAL cell-spots and 
cryosections was performed as described previously [47, 111, 130, 180] using anti-
CD11b (101202, clone M1/70 BioLegend) to detect blood and inflammatory 
macrophages, anti-CD11c (M100-3, clone 223H7, MBL International, Woburn, MA) to 
detect alveolar macrophages and dendritic cells, anti-CD45 (103102, clone 30-F11, 
BioLegend) for total leukocytes, anti-Ly-6G (127602, clone 1A8, BioLegend) to detect 
neutrophils, and anti-Ly-6C (128001, clone HK1.4, BioLegend) to detect a variety of 
inflammatory immune system cells, and with isotype-matched irrelevant antibodies 
(BioLegend) as controls. SDS-PAGE analysis of BAL, and nanodrop protein assays, 






4.3.11. Hydroxyproline assay 
Hydroxyproline assays were performed as described previously [180] with the 
exception that approximately half lobes of lungs frozen in OCT were cut off in three 
pieces, thawed, and washed three times with 0.5 ml PBS to remove OCT by 
centrifugation at 2000 × g for 5 minutes in pre-weighed Eppendorf tubes. After the last 
centrifugation, the tubes were kept inverted for 5 minutes to allow PBS to blot onto 
blotting paper, and the tissue was then weighed. Tissues were then processed using a 
hydroxyproline quantification kit (MAK008-1KT, Sigma-Aldrich) following the 
manufacturer’s directions. 
 
4.3.12. Statistical analysis 
Data were analyzed by t-test or ANOVA using Prism 7 (GraphPad, La Jolla, 
CA). Significance was defined as p < 0.05. IC50 curves for enzyme assays were 
generated using the Dose Response - Inhibition curve fitting model with variable slope 
with Prism 7. 
 
4.4. Results 
4.4.1. Recombinant human NEU3 desialylates recombinant human LAP and 
releases active TGF-β1 
Neuraminidases from influenza virus and bacteria remove sialic acid from the 
LAP protein, which causes the LAP to release active TGF-β1 [92, 93, 210]. To 




(rhLAP), we incubated recombinant human sialidases (made in HEK293 cells) or C. 
perfringens neuraminidase [47] with rhLAP. Western blots of the rhLAP were stained 
with Sambucus nigra lectin to detect sialic acids [36, 245]. NEU3, NEU4, and C. 
perfringens neuraminidase significantly decreased sialic acid on rhLAP (Figures 31 a 
and b).  
 
We previously found that the addition of recombinant human NEU3 (rhNEU3) to 
human immune cells, pulmonary fibroblasts, and small airway epithelial cells causes 
them to upregulate extracellular and intracellular TGF-β1 [160]. To determine if NEU3 
causes recombinant human latent TGF-β1 (rhL-TGF-β1) to release active TGF-β1, we 
incubated rhL-TGF-β1 with rhNEU3, and measured released active TGF-β1. rhNEU3 
did cause a release of active TGF-β (Figure 31 c). Together, these results suggest that 
NEU3 removes sialic acid from the LAP protein and releases active TGF-β1 from rhL-
TGF-β1.  
 
The standard assay for sialidases is cleavage of the fluorogenic substrate 2′-(4-
Methylumbelliferyl)-α-D-N-acetylneuraminic acid (4MU-NANA) [134]. At 
concentrations of rhNEU3 up to 100 ng/ml (1.94 nM), and using 4MU-NANA with no 
enzyme as a control, we were unable to detect statistically significant activity of rhNEU3 
on 4MU-NANA. Compared to commercially available HEK-293 cell-synthesized 
rhNEU3, we were able to purify much higher amounts of a bacterially expressed fusion 





Figure 31. Recombinant human NEU3 releases active TGF-β1 by desialylating 
recombinant human latency associated protein (LAP). 
(a) Recombinant human LAP protein was incubated with or without recombinant human 
sialidases NEU 1 – 4 or C. perfringens neuraminidase, and a western blot was stained 
with Sambucus nigra lectin (SNA) (top panel), to detect sialic acids on glycoconjugates. 
Black bands are the LAP protein. Silver staining (bottom panel) was done as a loading 
control. Blots and silver staining are representative of three independent experiments. 
Degradation products from the sialidases are also visible in the silver stained gel in 
addition to the LAP protein. (b) The western blots from (A) were quantified for 
Sambucus nigra staining of LAP protein. Values are mean ± SEM, n = 3. ** p ≤ 0.01 (1-
way ANOVA, Bonferroni’s test compared to control). (c) An ELISA assay, specific for 
active TGF-β1, was performed on recombinant human latent-TGF-β1 (rhL-TGF-β1) 
treated with the indicated concentrations of recombinant human NEU3. Values are mean 
± SEM, n = 6. Purified bacterially expressed recombinant human MBP-NEU3 was 
assayed for effects on (d) rhL-TGF-β1 and (e) hydrolysis of the substrate 4MU-NANA 
to release fluorophore 4MU. Values are mean ± SEM, n ≥ 3. (f) Release of active TGF-
β1 as a function of time by 1.94 nM recombinant human NEU3 from 3 nM rhL-TGF-β1. 
Values are mean ± SEM, n = 4. (g) Kinetics of recombinant human NEU3 activity in the 
TGF-β1 release assay. Values are mean ± SEM, n = 4. 
 
(brhNEU3; Figure 32 a and b). The ~93 kDa brhNEU3 contained a contaminant band 
that stained weakly for NEU3 on western blots (Supplemental Figure 1A and B), so the 
concentration of bhrNEU3 was estimated by comparison of the ~93 kDa band to BSA 




rhL-TGF-β1, albeit with somewhat lower efficacy than rhNEU3 (Figures 31 c and d). 
Compared to rhL-TGF-β1 as a substrate, a much higher concentration of brhNEU3 was 










A previous study with 4MU-NANA as the substrate for NEU3 reported a Km of 
45 ± 3 μM and a kcat of 0.33 ± 0.02 min
-1 and thus a catalytic efficiency kcat / Km of 0.007 
± 0.006 µM-1 min-1 [241]. Using rhL-TGF-β1 as the substrate for rhNEU3, and, 
measuring the rate of TGF-β1 release for different concentrations of rhL-TGF-β1 
(Figures 31 f and g), we observed a Km of 1.5 ± 0.5 nM and a kcat of (4.0 ± 0.4) x 10
-5 
min-1 (both mean ± SEM, n = 4), and thus a kcat / Km of 0.026 ± 0.008 µM
-1 min-1. The 
lower Km and higher kcat / Km for rhL-TGF-β1 compared to 4MU-NANA suggest a 
Figure 32. Recombinant human NEU3 purified from bacteria. 
(a) A western blot of purified MBP-NEU3 was stained with anti-NEU3 antibodies, 
showing a band at the expected molecular mass of ~93 kDa, (b) A gel of the indicated 





higher affinity of NEU3 for rhL-TGF-β1 compared to 4MU-NANA as a substrate. 
Together, these results suggest that rhL-TGF-β1 can be used as a better substrate than 
4MU-NANA for a more sensitive assay to determine NEU3 activity.  
 
4.4.2. Design of NEU3 inhibitors 
We designed possible inhibitors of human NEU3 based in part on the structure of 
2,3-didehydro-2-deoxy-N-acetyl-neuraminic acid (DANA) (Figure 33 a), a known 
inhibitor of NEU3 (Ki = 30 μM) [239]. DANA contains a double bond, of which the sp
2-
hybridized carbon-2 (circled) may be a structural mimic of the putative oxacarbenium 
ion intermediate (OCI) (Figure 33, a and b) of the chemical mechanism of enzymatic 
catalysis [241]. As DANA lacks the positive charge of the OCI, a better mimic of this 
putative reaction intermediate is likely afforded by the tetrahydropyridine-1-ium-2-
carboxylate (THPC) (Figure 33 c) which provides the positive charge, but at the expense 
of sp2-hybridized carbon-2. Consequently, we pursued substituted picolinic acids, which 
contain both a cationic nitrogen atom and sp2-hybridization at carbon-2 (Figure 33 d), as 
well as a substituted pipecolinic acid (compounds 3-5 in Table 3). 
 
4.4.3. Compounds 3 – 5 from Table 3 inhibit NEU3 release of TGF-β1 
 To test the hypothesis that compounds 3-5 inhibit NEU3, we assayed their effects 
in the rhNEU3 - rhL-TGF-β1 release of active TGF-β1 reaction (Table 3 and Figure 34).  














Table 3. Compounds used in NEU3 activity assays. 
List of commercially available compounds used in the NEU3 induced release of active 
TGF-β1 assay and the cell-based NEU3-induced upregulation of IL-6 assay to determine 
IC50. The IC50 values are mean ± SEM, n ≥ 3. 
 
 
Figure 33. Schematic representation of the rationale for design of NEU3 
inhibitors. 
Structures of (a) 2,3-didehydro-2-deoxy-N-acetyl-neuraminic acid (DANA), (b) the 
predicted oxacarbenium ion intermediate (OCI), (c) tetrahydropyridine-1-ium-2-






Figure 34. Inhibition of recombinant human NEU3-catalyzed release of active          
TGF-β1 by compounds from Table 3. 
Compounds labelled on the X-axis of graphs (a) to (e) were incubated at the indicated 
concentrations with and without recombinant human NEU3 in PBS pH 6.9. rhL-TGF-β1 
was added as substrate, and the release of active TGF-β1 was quantified by an ELISA 
kit. Values are mean ± SEM, n ≥ 3. The NEU3-catalyzed release of active TGF-β1 was 
determined by subtracting active TGF-β1 values in the absence of NEU3 from active 
TGF-β1 values in the presence of NEU3 in the data from (a – e). The baseline corrected 
values were normalized to the percent of active TGF-β1 in the absence of the compound 
(0 μM of inhibitor). (f) – (g) IC50 values (red lines) were determined from the normalized 
values by non-linear regression curve fitting. Values are mean ± SEM, n ≥ 3. 
 
 
(MP) had higher potencies of inhibiting rhNEU3 activity compared to DANA and 
oseltamivir phosphate (Tamiflu) (Table 3, Figure 34 a – d and f – i), which supported 
our rationale for potential NEU3 inhibitors. The fully-saturated pipecolinic acid 
compound, 4-amino-1-methyl-2-piperidine carboxylic acid (AMPCA), was also a very 
potent inhibitor of NEU3 (Table 3, Figure 34 e and j) despite its lack of an adjacent sp2-
hybridized carbon as in the case of the picolinate inhibitors. These results suggest the 
cationic nitrogen and an adjacent keto or carboxylate group provided the essential 




enzymatic transition state structure, and that these inhibitors are significantly improved 
over DANA and oseltamivir when rhL-TGF-β1 is the substrate. 
 
 
Figure 35. Inhibition by compounds from Table 3 of recombinant human NEU3-
induced extracellular accumulation of IL-6 from human PBMCs. 
Compounds labelled on the X-axis of graphs (a) to (e) were incubated at the indicated 
concentrations with and without recombinant human NEU3 in serum free media. After 
30 minutes, human PBMCs were added and incubated at 37 °C, 5% CO2.  48 hours later 
media supernatants were assayed for IL-6. Values are mean ± SEM, n ≥ 3. The NEU3-
induced extracellular accumulation of IL-6 was determined by subtracting IL-6 values in 
the absence of NEU3 from IL-6 values in the presence of NEU3 in the data from (a – e). 
The baseline corrected values were normalized to the percent of IL-6 value in the 
absence of the compound (0 μM of inhibitor). (f) – (j). IC50 values (red lines) were 
determined from the normalized values by non-linear regression curve fitting. Values are 
mean ± SEM, n ≥ 3. 
 
4.4.4. Compounds 3-5 inhibit NEU3-induced extracellular accumulation of           
IL-6 by human immune cells 
 rhNEU3 upregulates extracellular accumulation of IL-6 from human PBMC 
[180]. We also measured the effects of inhibitors in a NEU3-induced IL-6 release by 
human immune cells assay (Table 3 and Figure 35). DANA, Tamiflu, 2AP, and MP all 




35 a – d and f – i). Compared to the other compounds, the pipecolinate AMPCA had an 
increased inhibition potency (Table 3, Figure 34 e and j). These results suggest that some 
picolinates and a pipecolinate can be used as inhibitors against NEU3 in cell-based or in-
vivo assays. The differences in inhibition potencies in the cell-based extracellular IL-6 
accumulation assay and in-vitro TGF-β1 based assay may be due to the presence or 
absence of factors that interact with NEU3 and/or the inhibitors in the cell-based IL-6 
assay compared to the buffer-based TGF-β1 release assay.  
 
4.4.5. NEU3 inhibitors inhibit mouse NEU3 
To determine if compounds 3-5 would be effective in mice, we tested them 
against recombinant mouse NEU3 in the NEU3-induced release of active TGF-β1 assay. 
The IC50 of 2AP was 0.8 ± 1.7 µM, MP was 3.2 ± 1.6 nM, and AMPCA was less than 1 
nM (Figure 36 A – F). These results suggest that the three selected NEU3 inhibitors are 
inhibitors of mouse NEU3.  
 
4.4.6. AMPCA attenuates weight loss of mice after bleomycin treatment  
To determine if NEU3 inhibitors affect bleomycin-induced pulmonary fibrosis, 
C57BL/6 mice were treated with an oropharyngeal aspiration of saline or bleomycin and 
then starting 10 days after saline or bleomycin, mice were given daily intraperitoneal 
injections of 1 mg/kg 2AP or MP, or 0.1 mg/kg AMPCA. As previously observed, 
compared to saline treated-control mice, bleomycin-treated control mice had lower body 




MP, and AMPCA did not significantly affect body weights. AMPCA attenuated the 
bleomycin-induced weight loss (Figure 37 a). 2AP, MP, and AMPCA did not 
significantly affect liver, heart, kidneys, spleen, white fat or brown fat weights as percent 
of total body weight (Figure 38 a – f). Together these results suggest that AMPCA 
attenuates bleomycin-induced weight loss in mice. 
 
 
Figure 36. NEU3 inhibitors inhibit recombinant mouse NEU3-catalyzed release of 
active TGF-β1. 
(a – c) The indicated compounds were incubated with and without recombinant mouse 
NEU3. rhL-TGF-β1 was added as a substrate, and the release of active TGF-β1 was 
quantified. Values are mean ± SEM, n ≥ 3. (d – f) IC50 values were determined as 





Figure 37. AMPCA attenuates bleomycin-induced decline in body weight and    
protein increase in the BAL fluid at day 21 after bleomycin treatment. 
(a) Percent change in body weight after saline (S) or bleomycin (B) treatment at day 0, 
and then at day 10 starting daily intraperitoneal injections of PBS (Ctrl), 2 acetyl 
pyridine (2AP), Methyl picolinate (MP), or 4-amino-1-methyl-2-piperidie carboxylic 
acid (AMPCA). Values are mean ± SEM, n = 3. * p ≤ 0.05 (t test). BAL fluid was 
collected at day 21 following saline or bleomycin (bleo) treatment and 2AP, MP, or 
AMPCA i.p. injections. (b) BAL fluids from the indicated mice were analyzed by PAGE 
gels stained with Coomassie. Molecular mass markers in kDa are at left and in the 
center. Bovine serum albumin (BSA) at 0.01, 0.1, 1.0, and 10.0 μg was loaded at right on 
each gel. (c) Quantification of protein by densitometry in lanes from panel a, using the 
BSA band densities as standards, and then for each mouse multiplying by the BAL 
volume to obtain total BAL protein. S indicates saline and B indicates bleomycin. (d) 
Quantification of protein from BAL as in panel b, using a nanodrop assay to obtain BAL 
protein concentrations and then for each mouse multiplying by the BAL volume to 
obtain total BAL protein. S indicates saline and B indicates bleomycin. For b and c, 






Figure 38. Injections of 2AP, MP, or AMPCA from day 10 after bleomycin    
treatment had no significant effect on organ weights. 
Weights of (a) Liver, (b) Heart, (c) Kidneys, (d) Spleen, (e) White fat, and (f) Brown fat 
as percent of total body weight at day 21 after saline (S) or bleomycin (B) treatment. 
Values are mean ± SEM, n = 3. There were no significant changes (1way ANOVA, 
Bonferroni's test).   
 
 
4.4.7. AMPCA attenuates protein increase in the BAL fluid at day 21 after 
bleomycin treatment 
 Bleomycin causes an increase in protein levels in the bronchoalveolar lavage 
fluid (BAL) from mouse lungs [111, 188, 189]. To determine if inhibiting NEU3 affects 
these BAL protein levels, we measured the protein in the BAL as a measure of lung 
tissue damage post bleomycin treatment. As observed previously [111, 180, 188, 189], at 




upregulated BAL protein levels (Figure 37 b – d). Compared to saline-treated control, 
the saline-treated 2AP, MP, or AMPCA injected mice had no significant difference in 
the levels of proteins in the BAL as assayed by either gel densitometry (Figure 37 b – c) 
or nanodrop (Figure 37 c). AMPCA treatment significantly attenuated the bleomycin-
induced increase of protein levels in the BAL (Figure 37 b – d). Although 2AP and MP 
seemed to decrease BAL protein levels in bleomycin-treated mice, the effect was not 
statistically significant. We previously observed that Tamiflu treatment, but not DANA 
treatment, attenuated bleomycin-induced increased protein levels in the BAL [160]. 
Together, these results suggest that some NEU3 inhibitors can attenuate bleomycin-
induced upregulation of protein levels in the BAL. 
 
4.4.8. NEU3 inhibitors attenuate the increased number of inflammatory              
cells in the BAL at day 21 after bleomycin treatment 
 Bleomycin aspiration also causes an upregulation of inflammatory cells in the 
BAL at day 21 [47, 107, 111, 130]. Compared to saline-treated control mice, the 
bleomycin- treated control mice showed upregulated BAL cell counts (Figure 39 a). The 
saline-treated control mice and saline-treated and 2AP, MP, or AMPCA injected mice 
showed similar BAL cell counts (Figure 39 a). Compared to saline-treated mice, 
bleomycin-treated and MP or AMPCA injected mice showed upregulated BAL cell 
counts, but these were significantly less compared to bleomycin-treated control mice 





Figure 39. 2AP, MP, or AMPCA from day 10 after bleomycin treatment decrease 
BAL cells. 
(a) The total number of cells in mouse BAL after the indicated treatment. S indicates 
saline and B indicates bleomycin. Values are mean ± SEM, n ≥ 3 mice per group. ** p < 
0.01, *** p < 0.001, and **** p < 0.0001 (1way ANOVA, Bonferroni's test). # p < 0.05 
and ## p < 0.01 (t-test). BAL cell-spots at day 21 were stained for the markers (b) 
CD11b, (c) CD11c, (d) CD45, (e) Ly6G, and (f) Ly6C. The percent of cells stained was 
determined in 5 randomly chosen fields of 100-150 cells, and the percentage was 
multiplied by the total number of BAL cells for that mouse to obtain the total number of 
BAL cells staining for the marker. Values are mean ± SEM, n = 3. * p < 0.05, *** p < 
0.001, **** p < 0.0001 (1-way ANOVA, Bonferroni's test), # p < 0.05, ## p < 0.01, and 
### p < 0.001 (t-test). 
 
resident alveolar macrophages (Figure 39 c), CD45 positive leukocytes (Figure 39 d), 
and Ly6G positive cells (Figure 39 e). Significant differences were not observed for 
Ly6C positive cells (Figure 39 f). The BAL of saline-treated control mice, and saline-




types (Figure 39 b – f). Compared to BAL from saline-treated mice, bleomycin-treated 
2AP or AMPCA injected mice showed upregulated counts of CD11b positive cells 
(Figure 39 b), CD11c positive cells (Figure 39 c), and CD45 positive cells (Figure 39 d) 
in the BAL, but these counts were significantly less compared to bleomycin-treated 
control mice. The MP injected mice did not show significantly increased counts of the 
above cell types in the BAL of saline-treated or bleomycin-treated mice (Figure 39 b – 
f). Together, these data suggest that NEU3 inhibitors attenuate the bleomycin-induced 
increase of inflammatory cell counts in the BAL. 
 
 Lung sections were also stained to detect inflammatory cells. As previously 
observed [180], bleomycin increased the counts of CD11b+, CD11c+, and CD45+ cells 
remaining in the lungs after BAL (Figure 40 a – c), but did not affect the counts of 
Ly6G+ or Ly6C+ cells (Figure 40 d – e). 2AP, MP, or AMPCA did not affect the counts 
of CD11b+ and CD11c+ cells (Figure 40 a – b), but 2AP and MP significantly 
counteracted the increase in CD45+ cells in the lungs after BAL at day 21 (Figure 40 c). 
Together, these results suggest that some NEU3 inhibitors attenuate the upregulation of 





Figure 40. Remaining immune cells in lungs post BAL. 
Cryosections of mouse lungs were stained for (a) CD11b, (b) CD11c, (c) CD45, (d) 
Ly6G, and (e) Ly6C, and cells in 5 randomly chosen 0.45 mm diameter fields of view 
were counted, and the number was then calculated to number per mm2. Values are mean 
± SEM, n = 3. * p < 0.05 (1-way ANOVA, Bonferroni's test). # p < 0.05 (t-test). 
 
4.4.9. NEU3 inhibitors decrease fibrosis 
 To determine if inhibiting NEU3 can decrease bleomycin-induced fibrosis, lung 
sections were stained with hematoxylin and eosin to detect tissue, picrosirius red to 
detect total collagen, and hydroxyproline levels were measured in the lung tissue lysates. 





Figure 41. 2AP, MP, or AMPCA injections starting at day 10 after bleomycin 
attenuate fibrosis. 
Sections of lung tissue from mice treated with saline or bleomycin, and then injected 
daily with control or 2AP or MP or AMPCA starting at day 10 after bleomycin, and then 
euthanized at day 21, were stained with (a) H&E, and (b) picrosirius red to show 
collagen content. All images are representative of 3 mice per group. In both (a) and (b), 
Bar is 200 μm. (c) Hydroxyproline in lungs. Values are mean ± SEM, n = 3. * p < 0.05 
and ** p < 0.01 (1-way ANOVA, Bonferroni's test). # p < 0.05 (t-test). (d) Picrosirius 
red quantification analyzed by selecting 5 random fields of view of the sizes shown in 
(B) for each mouse, and the average percent area of the field of view showing staining 
for each mouse was measured. Values are mean ± SEM, n = 3. **** p < 0.0001 (1-way 
ANOVA, Bonferroni's test). # p < 0.05 (t-test). 
 
mouse lungs at day 21 (Figure 41 a – d and Figure 42). Compared to saline treatment, 
lungs from mice exposed to bleomycin and then treated with MP showed increased 
Sirius red staining and hydroxyproline levels at day 21 (Figure 41 b – d). The Sirius red 
staining and hydroxyproline levels from bleomycin treated and then 2AP, MP, or 
AMPCA treated mice was significantly less than the bleomycin-treated control mice 






Figure 43. 2AP, MP, or AMPCA injections starting at day 10 after bleomycin    
reduces TGF-β1 staining.  
(a) Sections of lung tissue from mice treated with saline or bleomycin, and then injected 
daily with control or 2AP or MP or AMPCA starting at day 10 after bleomycin, and then 
euthanized at day 21, were stained with antibodies against TGF-β1. All images are 
representative of 3 mice per group. Pink is staining, blue is counterstain. Bar is 200 μm. 
(b) Quantification of staining analyzed by selecting 3 random fields of view of the sizes 
shown in (A) for each mouse, and the average percent area of the field of view showing 
staining for each mouse was measured. Values are mean ± SEM, n = 3. * p < 0.05 (t-
test). 
 
treatment showed reduced staining for active TGF-β1 in the lung sections compared to 
bleomycin-treated control mice (Figures 43 a – b). These results suggest that NEU3 
inhibitors reduce bleomycin-induced fibrosis and TGF-β1 upregulation in mouse lungs. 
 
Figure 42. Picrosirius red staining of lung cryosections. 
Representative mosaic images of mouse lung cryosections stained with Sirius red. Images are 
representative of 3 mice aspirated with saline or bleomycin and injected with (a) PBS as control, 
(b) 2-acetyl pyridine (2AP), (c) Methyl picolinate (MP), or (d) 4-amino-1-methyl-2-piperidine 





In this report, we observed that the human sialidase NEU3 desialylates human 
LAP and causes release of active TGF-β1. This is in agreement with the observation that 
LAP desialylation by viral and bacterial sialidases [93, 210] causes a conformational 
modification of the LAP which results in disruption of the interaction between LAP and 
active TGF-β1, releasing active TGF-β1 [211]. Compared to the more conventional 
mechanism of a cell sensing a signal, and activating a gene expression pathway to make 
and secrete a responding signal, the desialylation of LAP and release of active TGF-β1 is 
a much more rapid response. This then suggests that fibrosis is associated with a 
mechanism that originally evolved to rapidly respond to an insult such as a sialidase-
expressing pathogen, with the extracellular NEU3 mimicking and thus amplifying the 
pathogen signal. 
 
NEU1 may also be involved in potentiating pulmonary fibrosis [37], but this 
sialidase did not significantly desialylate LAP, suggesting that it may act by other 
mechanisms to promote fibrosis. NEU4 did desialylate LAP, but since this sialidase is 
present in lysosomes [157] or mitochondria and endoplasmic reticulum [246, 247], it 
either does not normally desialylate LAP, or NEU4 from necrotic or otherwise lysed 
cells may normally desialylate LAP. 
 
We used a predicted reaction intermediate from the NEU3 reaction mechanism 




nitrogen replacing the putative positively-charged oxygen of the reaction intermediate 
could act as NEU3 inhibitors. In both the TGF-β1 release from LAP and the IL-6 
production by PBMC assays, we observed significantly improved inhibition potency of 
AMPCA compared to DANA or oseltamivir (Table 1). Since some tumors have 
upregulated NEU3 [55-57, 248], and since mice lacking Neu3 are resistant to colitis-
associated colon tumor formation [178], AMPCA or similar compounds may useful to 
treat NEU3-associated tumors. 
 
NEU1 and NEU2 do not significantly desialylate LAP, and thus this assay was 
incompatible for determining inhibition potencies of our compounds against NEU1 and 
NEU2. The extracellular pH of lesions in lung fibrosis ranges from 6.45 to 6.95 [158]. 
Our repeated efforts to assay NEU1, NEU2, and NEU4 in this pH range with the 
substrate 4MU-NANA were unsuccessful. Thus, it is unclear if our compounds inhibit 
sialidases other than NEU3. 
 
As with AMPCA, DANA and Tamiflu attenuated bleomycin-induced protein 
upregulation in the BAL at day 21 [160]. However, 2AP or MP did not significantly 
attenuate bleomycin-induced protein upregulation in BAL at day 21. These disparate 
results may be due to dose effects, or due to effects that DANA, Tamiflu, 2AP, MP, and 





We previously observed that NEU3 is upregulated in the mouse bleomycin 
model, and that inhibition of sialidases with DANA or oseltamivir, or loss of NEU3, 
attenuate bleomycin induced pulmonary fibrosis in mice [160, 180]. The human and 
mouse NEU3 inhibitors 2AP, MP, and AMPCA all inhibited pulmonary inflammation, 
levels of active TGF-β1 in the lungs, and pulmonary fibrosis in the mouse bleomycin 
model. The Uniprot sequences P01137 for human L-TGF-β1 and P04202 for mouse L-
TGF-β1 show 90% amino acid sequence similarity and conserved glycosylation sites 
[249-252]. A reasonable explanation for the ability of NEU3 inhibitors to decrease 
bleomycin-induced increased levels of active TGF-β1 is that mouse NEU3 also 
desialylates mouse LAP to release mouse TGF-β1. Together, these results support the 
hypothesis that a positive feedback loop where NEU3 desialylates LAP to release active 
TGF-β1, and the active TGF-β1 causes lung epithelial cells to increase translation of 
NEU3 mRNA and decrease degradation of NEU3 protein [231], contributes to 





5. CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1. Conclusions 
Overall, my dissertation has focused on understanding the contributions of 
sialidases to the pathophysiology of IPF and designing potential therapeutic 
interventions to halt IPF progression in patients. Over the years, a great amount of 
research has been conducted to understand the pathophysiology of IPF with the 
objectives of developing potential therapeutics to inhibit IPF progression. However, 
these studies have failed to determine a single protein or factor that causes the 
progression of IPF. Currently, there are only two FDA approved therapeutics which slow 
down, but not inhibit the progression of IPF. 
 
Previous data from our lab had indicated that a serum protein called serum 
amyloid P, (SAP), attenuated fibrosis-associated cell differentiation and could be used as 
a potential therapeutic to inhibit IPF progression [15, 111, 253]. When SAP is sialylated, 
it can attenuate fibrosis-associated cell differentiation, but when SAP is desialylated, it 
loses the ability to inhibit the fibrosis-associated cell differentiation [17]. This 
desialylation is carried out by sialidases. There are 4 different types of sialidases present 
in mammals, NEU1 – 4 [52]. 
 
We first sought to identify which sialidases among NEU1 – 4 are responsible for 




sialidases, NEU2 and NEU3, in both human lung fibrotic lesions and in a bleomycin-
induced pulmonary fibrosis mouse model. In support of the previously reported effects 
of desialylated SAP [17], I show that treatment with recombinant human NEU2 or 
NEU3 counteracts SAP’s ability to inhibit of fibrosis-associated cell differentiation. In 
addition, sialidase NEU3 was upregulated in the bronchoalveolar lavage (BAL) lung 
fluid of a fibrotic mouse lung. In a cell-based in-vitro study, human PBMC’s incubated 
with recombinant human NEU3 upregulated the levels of active TGF-β1, which is one of 
the many reported factors promoting IPF development [84, 88]. Conversely, different 
lung cell types incubated with active TGF-β1 showed upregulated sialidases expression, 
and this upregulation was primarily made up of NEU3. Thus, in these studies, I found 
that sialidase NEU3 is upregulated in the fibrotic lesions of the lung, and that NEU3 
potentiates the upregulation of active TGF-β1 levels. 
 
Many studies strongly imply that active TGF-β1 plays an important role in the 
development of IPF [84, 88, 91]. The sequestration protein LAP keeps TGF-β1 in its 
inactive form [89]. Both LAP and TGF-β1 exists as a complex of dimers called latent-
TGF-β1 [86, 90]. In this complex, LAP exists as a glycoconjugate which when 
desialylated, releases the active TGF-β1 [22, 92, 93, 96, 212]. Although a considerable 
amount is known about the release of TGF-β1 from its sequestering protein LAP [84, 91, 
221, 254, 255], relatively little is known about the release of TGF-β1 from its inactive 
latent form at the fibrotic lesion site within the lungs. In this dissertation, I report a 




form in lung fibrosis. I report that recombinant human NEU–3 acts on recombinant 
human latent-TGF-β1 and desialylates LAP, which leads to the release and eventually, 
the upregulation of active TGF-β1. This suggests that upregulated levels of NEU3 in 
fibrotic lesions plays an important role in activating TGF-β1. All of these results suggest 
there is a positive feedback loop, where high levels of sialidase NEU3 increase active 
TGF-β1 levels, and upregulated active TGF-β1 increases sialidases in different lung cell 
types and primarily at the active site of a fibrotic lesion. 
 
Subsequently, we sought to validate this hypothesis in mouse models. We wanted 
to see if we could prevent the progression of pulmonary fibrosis when NEU3 is not 
present. To this end, we used NEU3 knockout mice [178] to validate the role of NEU3 in 
the pulmonary fibrosis positive feedback loop. Compared to wild-type mice, mice 
lacking NEU3 have significantly less bleomycin-induced pulmonary fibrosis, and 
attenuated levels of upregulated TGF-β1 in the lungs. In addition, mice lacking NEU3 
have reduced protein leakage, cell infiltration, and IL-6 levels in the BAL lung fluid, 
which are recognized as some of the hallmark features of bleomycin-induced pulmonary 
fibrosis in a mouse model. These results provide genetic evidence that NEU3 plays a 
role in pulmonary fibrosis progression in mice. Taken together, these results suggest that 
inhibiting sialidases could be useful strategy to break the positive feedback loop and 





Burmeister et al. and Kim et al. showed two small molecules, DANA and 
oseltamivir phosphate (Tamiflu) can be used as sialidase inhibitors [155, 238, 239, 256, 
257]. In addition, I show that both DANA and Tamiflu strongly attenuate sialidase-
induced upregulation of fibrosis-associated signals like TGF-β1 and IL-6 in in-vitro cell-
based studies. In the bleomycin-induced pulmonary fibrosis mouse model, daily 
intraperitoneal injections of either DANA or oseltamivir at 10 mg/kg, starting from day 
10 after bleomycin assault, strongly attenuated pulmonary fibrosis at day 21. However, 
DANA and oseltamivir (Tamiflu) only work well on viral and mouse sialidases [159]. 
Both DANA and oseltamivir (Tamiflu) work poorly on human sialidases [155, 159, 
238]. Hence, we designed a new class of small molecule NEU3 inhibitors based on 
DANA as the parent molecule [239-241]. Some of the designed inhibitors have 
nanomolar – picomolar potency for inhibition of recombinant human NEU3-induced 
release of active TGF-β1 from the recombinant human latent TGF-β1. Three of these 
small molecule inhibitors, 2-acetyl pyridine (2AP), methyl picolinate (MP), and 4-
amino-1-methyl-2-piepridine carboxylic acid (AMPCA), were given as daily 0.1 mg/kg 
or 1 mg/kg injections starting on day 10 and strongly attenuated most of the pulmonary 
fibrosis-associated characteristics on day 21 in the bleomycin-induced fibrosis mouse 
model. Together, these results suggest that sialidase NEU3 potentiates fibrosis, and that 
NEU3 could be a useful target to treatment fibrosis. 
 
Thus, I can summarize my dissertation as containing major contributions to the 




fibrosis – NEU3 in IPF progression, the elucidation of a possible mechanism for NEU3 
induced activation of TGF-β1 in pulmonary fibrosis, the identification of existing 
sialidase inhibitors for off-label uses as a stand-alone therapy against pulmonary fibrosis, 
and finally, the invention and validation of new class of inhibitors against sialidase 
NEU3 as potential therapeutics for pulmonary fibrosis, which can also be studied as 
therapeutics for other NEU3-induced diseases. 
 
5.2.  Future directions 
5.2.1. Structural studies of the NEU3 with novel inhibitors 
One possible future direction for this project is the study of the crystal structure 
of NEU3 complexed with some of our proposed novel inhibitors. There is an urgent need 
to have a crystal structure of NEU3, which can help us understand any structural 
differences between the different isoforms of mammalian sialidases. Such studies can 
help us to better understand the substrate specificities and rationale of the different 
substrate recognition by NEU3. Also, such studies can provide useful insights into 
efficient structure-based design for specific inhibitors for the different mammalian 
sialidases.  
 
5.2.2. Study the inhibition potency of our sialidase inhibitors on other           
sialidase isoforms 
An immediate continuation for this project is to study the inhibition potency of 




NEU2, or NEU4 in a physiological pH range of 6.45 to 7.0 with a commonly used 
fluorogenic sialidase substrate, 4MU-NANA, were inconclusive. One possible 
explanation could be that the reported optimal pH for NEU1, NEU2, or NEU4 assays is 
from pH 4.4 to 6.0 [52].  A cell culture-based assay to study sialidase activity or 
sialidase inhibition would be more useful. One such sialidase activity through a cellular 
response has been reported with Jurkat T-cells lines, which when incubated with NEU1, 
upregulated interleukin-4 (IL-4) levels [34]. This property of Jurkat T-cells acting in 
response to NEU1 can be utilized to study the inhibition efficiency and specificity of our 
sialidase inhibitors against NEU1. A carefully designed dosing study of the inhibitors 
can help avoid initiating a NEU1-deficient pathological condition called sialidosis. A 
few studies report NEU1 upregulation in pulmonary fibrosis and other inflammatory 
diseases [34, 53, 123, 126]. Thus, detailed and thorough studies on the inhibition 
potencies of our new class of sialidase inhibitors on sialidases other than NEU3 can help 
develop potential therapeutics for diseases caused by the upregulation of a specific 
sialidase. 
 
5.2.3. Development of potential therapeutics from the proposed sialidase          
NEU3 inhibitors 
The work of my dissertation has guided us to single out one sialidase, NEU3, 
which when inhibited has a significant effect in attenuating pulmonary fibrosis in mouse 
model studies. A future direction for this project is to promote our NEU3 inhibitors as 




Our studies show that the daily administration of sialidase inhibitors like DANA, 
Tamiflu, 2AP, MP, or AMPCA, showed no discernable effects on the normal mouse 
physiological conditions in the animal model studies. This suggests that the 
aforementioned inhibitors can be promoted for clinical trials and we should continue 
efforts to establish them as potential therapeutics against pulmonary fibrosis. Many other 
studies report that upregulated NEU3 helps cancer cells to evade apoptosis and thus, 
NEU3 potentiates their survival [52, 55-57, 248]. An exciting new future direction 
would be a study of NEU3 inhibitors and their effects on cancer cell apoptosis to 
determine if NEU3 inhibitors can contribute to the development of therapeutics for 
NEU3-induced cancers.  
 
 The growing evidence of sialidase/ neuraminidase involvement in human diseases 
emphasizes the need of further studies to determine the overall activity of sialidases, and 
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